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 Prostate cancer, being one of the most commonly diagnosed cancers in 
the United States, contributes to the second leading cause of cancer morbidity. 
In Singapore, prostate cancer ranks the third most common cancer amongst 
the diagnosed males. Manifestations of the disease can range from an 
asymptomatic state to the severe life-threatening form, posing therapeutic and 
diagnostic challenges. A deeper understanding of prostate cancer at the 
molecular level can help identify potential therapeutics and thus improve the 
management of this disease. Moreover, biomarkers are in need to facilitate a 
better prediction of clinical outcomes and stratification of patients into the 
appropriate treatment plans.  
Glycosaminoglycans have been found to participate in various cellular 
signaling events and are important regulators of tumour metastasis. 
Microarray analysis from a previous study (Teng, 2010) has indicated a 
downregulation of HS3ST3B1 in both prostate cancer cell lines and tissues. 
The expression level of HS3ST3B1, a gene involved in heparan sulphate 
biosynthesis, was verified in prostate cancer cell lines LNCaP and PC-3. 
Silencing of this gene was then carried out in normal prostate epithelial cell 
line RWPE-1. Downregulating HS3ST3B1 has promoted cellular migration, 
invasion and proliferation as well as inhibited cellular adhesion via an 
upregulation of OPN3. These results point to the potential role of HS3ST3B1 
as a novel therapeutic target. OPN3 was subsequently silenced in RWPE-1 to 
determine its functions in normal prostate physiology.  
To explore the plausible application of HS3ST3B1 as a biomarker of 
prostate cancer progression, immunohistochemistry was performed to 
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correlate its expression in prostate adenocarcinoma tissues with established 
clinicopathological parameters. It was found that high HS3ST3B1 expression 
is associated with a lower risk of extraprostatic extension and perineural 
invasion as well as cancer involving unilateral lobe and lower pT2 stage and 
this may hence predict a better prognosis. 
On the whole, my findings established the anti-tumour role of 
HS3ST3B1 in prostate cancer cellular behaviour and suggested it to be a good 
biomarker of prostate cancer progression. Slight inconsistencies between in 
vitro and immunohistochemistry results nonetheless warrant further 
investigation to determine if HS3ST3B1 should play a greater role in terms of 
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1.1 Prostate Gland and Prostate Cancer  
 
1.1.1 The Anatomy of the Prostate Gland 
 
 The prostate lies between the urogenital diaphragm and bladder neck. 
With the base of the prostate contiguous with the bladder neck, skeletal 
muscle fibres from the urogenital diaphragm extend into its apex up to the 
midprostate anteriorly. Though there are no distinct lobes in humans, the lobal 
concept of prostate anatomy was sustained in the twentieth century till the 
1960s when McNeal established the zonal concept of the prostate gland 
(Brooks, 2007; Hammerich, 2009).  
The prostate is made up of approximately 70% glandular elements and 
30% fibromuscular stroma (Brooks, 2007). The zonal anatomy of the prostate 
gland describes four basic anatomic regions: the peripheral, central, transition 
and the anterior fibromuscular stroma. The peripheral zone constitutes more 
than 70% of the glandular prostate and consists of ducts branching laterally 
from the urethra. The cone-shaped central zone constitutes 25% of the 
glandular prostate. No major ducts arise in the transition zone, which 
combines with tiny periurethral ducts to form the preprostatic region of the 
prostate gland. The anterior fibromuscular stroma, a thick nonglandular tissue, 
surrounds the prostate’s anterior surface (Hammerich, 2009; McNeal, 1981).  
 These aforementioned zones of the glandular prostate are usually 
associated with specific prostate pathology. Almost all prostate carcinoma 
cases occur within the peripheral zone while the transition zone is more 
commonly involved in benign prostatic hyperplasia (BPH). 
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 Notably, the seminal vesicles which are located superiorly to the base 
of the prostate are resistant to nearly all prostate diseases. Seminal vesicle 
involvement (SVI) is henceforth one of the most important predictors for 
prostate cancer progression (Hammerich, 2009). 
 In the context of prostate cancer progression when lymph node 
involvement occurs, it is important to understand that lymphatic drainage in 
the glandular prostate passes mainly through the obturator and internal iliac 
nodes. A small portion however, may pass through the external iliac nodes 
(Brooks, 2007). 
 
1.1.2 Functions of the Prostate Gland 
 
 The prostate is an accessory sex gland which serves to support the sperm 
function. The acini of the prostatic ducts are composed of secretory, basal and 
neuroendocrine cells. The epithelial secretory cells produce both the prostate-
specific antigen (PSA) and prostate acid phosphatase (PAP) (Kaisary, 2009). 
The prostatic fluid contains citric acid, PAP, prostaglandins, fibrinogen and 
PSA. PSA, which is also a diagnostic marker, serves as a serine protease that 
liquefies semen after ejaculation (Louis, 2011).  
 
1.1.3 Epidemiology of prostate cancer 
 Prostate cancer is the second leading cause of cancer morbidity in the 
United States. In 2012, it was postulated that approximately 1 in 6 of 
American men will be diagnosed with the disease (Brawley, 2012). 
Prostate cancer is often termed as a disease of the older men. The 
median age at diagnosis was 67 years between 2001 and 2010. With the 
prevalence of PSA screening, there is an increased proportion of men being 
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diagnosed with localized disease. Notably, less than a third diagnosed with 
metastatic disease survive beyond 5 years (Brawley, 2012). 
It has also been estimated that more than half of screen-detected 
cancers are tumours insignificant to the patient’s health (Etzioni et al., 2002). 
Welch and Albertsen have also observed significant unnecessary prostate 
cancer treatment (Welch and Albertsen, 2009). Though the assessment of 
grade, percent of tumour in the biopsy and staging are important measures of 
outcome, they may not predict clinical outcome perfectly (Brawley, 2012). 
This thus necessitates better prognostic tools. 
 
1.1.4 Histopathology of the Prostate Gland 
 
1.1.4.1 Normal histology of the prostate 
 Columnar secretory cells line the ducts and acini of the prostate gland. 
These ducts and acini are regularly spaced and are smaller (0.15 to 0.3 mm in 
diameter) in the peripheral and transition zones in contrast to the central zone 
(0.6 mm in diameter or larger). Within the peripheral and transition zones, the 
ducts and acini have simple rounded contours with undulations from the 
epithelial border. The central zone however, has ducts and acini that are 
polygonal in contour. Distinctive intraluminal ridges form the corrugations 
observed in the walls of the central zone (McNeal, 1998). 
 Importantly, a layer of basal cells separates the secretory cells from the 
stroma and basement membrane. These basal cells would normally divide and 
mature into secretory cells which produce PSA, PAP, pepsinogen II and tissue 
plasminogen activator (McNeal, 1998).   
 Within the peripheral and transition zones, the secretory cells have 
smaller nuclei that are more evenly spaced. Cells are more uniformly 
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columnar and the cytoplasm has numerous vacuoles. The central zone in 
comparison has crowded columnar secretory cells with more granular 
cytoplasm and larger nuclei (McNeal, 1998). 
  
1.1.4.2 Histopathology of Prostate Adenocarcinoma  
 
 The diagnosis of prostate adenocarcinoma relies on a combination of 
architectural and cytologic features as summarized in the following table 
(Table 1.1)(Montironi R., 2007): 
 
Table 1.1 Architectural and cytologic features of prostate adenocarcinoma 
Diagnostic features of prostate adenocarcinoma 
Malignant acini patterns:  
- irregular and haphazard 
- wide variation of acini spacing 
- variation in size 
- irregular contour 
Architectural features 
Absence of basal cell layer 
Hyperchromatic nuclei 
Enlarged nuclei 







1.1.5 Gleason grading of prostate cancer 
 
 The Gleason grading system for prostate cancer introduced in 1966 
(Petersen R.O., 2009), the predominant grading system and strongest 
prognostic factor of a patient’s time to progression, is named after Donald F 
Gleason. This system constitutes of 5 different grades based on glandular 
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architecture. An increasing scale signifies a greater extent of de-
differentiation. Gleason grade 1 or 2 (well differentiated) prostate cancer is 
characterized by proliferation of microacinar structures. Enlarged nucleoli are 
evident. Gleason grade 5 being the highest grade includes infiltrating 
individual cells (Montironi R., 2007).  
As prostate cancer is usually heterogeneous, the primary (most 
prevalent) and secondary (second most prevalent) grades are summed to 
obtain a Gleason score. Score possibilities can thus range from 2 (1 + 1) to 10 
(5 + 5) (Hammerich, 2009). 
 Gleason grading is a significant factor in clinical decision-making as it 
predicts the pathologic stage, local recurrences, lymph node status, likelihood 
of disease progression and distant metastasis etc. Gleason scores of 7-10 have 
been associated with a worse prognosis while a lower progression rate for 
scores 5-6. Recently, Gleason score forms part of clinical nomograms to help 
predict disease progression. The various Gleason grades are as summarized 
below (Table 1.2)(Montironi R., 2007): 
 
Table 1.2 Gleason grades 
Gleason grades 
Grade 1: single and closely packed acini 
Grade 2: single acini that are more loosely arranged and less uniform 
Grade 3: single acini, cribriform and papillary patterns can be observed 
Grade 4: irregular masses of acini and fused epithelium 
Grade 5: anaplastic carcinoma 
 
 
 Though the Gleason system is being internationally recognized, there 
are issues of concern. Notably, Gleason grading is subjected to an observer’s 
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experience. Such inter- and intra-variability would exist but attempts have 
been made to improve diagnostic accuracy by exposure to computer-teaching 
programmes of Gleason grading (Petersen R.O., 2009). As the majority of 
patients fall into the Gleason 6-7 category, the usefulness of a 10-point scale is 
hugely compromised. Nonetheless, Gleason grading has been often 
incorporated with other histologic parameters such as the presence of 
extracapsular extension, surgical margin and lymph node status, seminal 
vesicle invasion and perineural invasion to better predict the time to 
progression (Hammerich, 2009). 
 
1.1.6 Clinical diagnosis and symptoms of prostate cancer 
 
 Prostate cancer is deemed asymptomatic and ‘clinically silent’. This is 
most likely due to its symptoms overlapping with other prostate diseases 
particularly BPH. Early manifestations can include bladder outlet obstruction, 
pelvic pain and rectal bleeding (Petersen R.O., 2009). Before prostate specific 
antigen (PSA) screening became widely employed as a diagnostic tool, digital 
rectal examination (DRE) was performed to detect palpable tumours 
(Montironi R., 2007). 
 DRE till now remains as the fundamental means of prostate tumour 
detection. This is followed subsequently by the most commonly used PSA test 
with an arbitrary cut-off level of 4.0 ng/ml. Nonetheless, some BPH 
conditions can present with a greater than 4.0 ng/ml level, compromising the 
sensitivity of PSA test. Additionally, men with higher risk of prostate 
carcinoma (family history and United States African American men etc) can 
present with serum PSA values lower than 4.0 ng/ml. This inevitably 
diminishes the specificity of PSA test. Nonetheless, adjustments have been 
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made to improve the accuracy of this paramount test by implementing 
complex PSA value, free-to-total PSA ratio, PSA density and PSA velocity 
(Montironi R., 2007). 
 Aside from laboratory tests, imaging techniques such as transrectal 
ultrasound imaging (TRUS) and Doppler ultrasound have been instrumental in 
prostate cancer diagnosis. Computed tomography and magnetic resonance 
imaging may facilitate the detection and staging of prostate cancer but have 
not proven valuable because of their low sensitivities (Montironi R., 2007). 
 Importantly, the gold standard for prostate cancer diagnosis is needle 
biopsies. Currently, the standard method is via transrectal ultrasound-guided 
core biopsies. In addition to the traditional sextant protocol which samples the 
apex, mid and base regions bilaterally, modifications have been made to 
sample the more lateral part of the peripheral zone where a significant number 
of cancers are located. Transition zone biopsies are also taken into 
consideration where a significant percentage (15 – 22%) of prostate cancers 
arise. The diagnosis of prostate cancer is confirmed through core biopsies, 
which have been essential in providing information about tumour extent and 
occasionally about extraprostatic extension and seminal vesicle invasion 
(Montironi R., 2007). 
There may be a group of patients who have been pronounced as “free 
of prostate cancer” after multiple negative biopsies but demonstrate 
continuously rising PSA level. These ‘suspicious patients’, particularly those 
with large prostates, should probably consider transurethral resection of the 
prostate (TURP). Studies have shown that despite a first negative biopsy, 
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TURP may disclose cancer in 4% to 28% of cases (Kitamura et al., 2002; 
Ornstein et al., 1997; Rovner et al., 1997). 
Kitamura et al. have concluded that TURP may not be very useful as 
many of the cancers diagnosed may be clinically insignificant. Nonetheless, 
there is still a significant proportion of missed diagnoses subsequently 
uncovered by TURP (Kitamura et al., 2002; Zigeuner et al., 2003). However, 
the downside of TURP is that it does not reach the lateral prostatic tissue. 
Hence, TURP should probably be combined with biopsies of the far lateral 
zone to improve cancer detection (Bratt, 2006; Puppo et al., 2006). 
 
1.1.7 Treatment 
 The array of treatment options is very much dependent on the age and 
staging of prostate cancer (American, 2012). Radical prostatectomy (RP) 
remains an excellent and mainstay treatment option for clinically localized 
prostate cancer. This surgical therapeutic option comprises of the open, 
laparoscopic or robotic-assisted types. Studies have indicated RP to be an 
effective procedure suggesting long term cancer control and freedom from 
cancer recurrence of 75% (Gibbons et al., 1989; Han et al., 2001). Currently, 
technical refinements have resulted in an improved urinary control and lower 
rates of positive surgical margins. 
 For over half a century, radiation therapy has played a significant role 
in treating prostate cancer. In fact, the two major therapeutic modalities for 
clinically localized prostate cancer comprise of RP and radiotherapy. With the 
introduction of the CT scanner and computer-based treatment planning 
software, target localization became much enhanced. Subsequently, intensity-
Introduction 
! *!
modulated treatment planning enabled dose escalation for better functional 
outcomes without added tissue toxicity. Radiotherapeutic options can include 
external beam radiotherapy or brachytherapy, either used as monotherapy or 
combined. Brachytherapy refers to the placement of radioactive sources at a 
close distance from or within the target tissue, very often being optimized with 
image guidance techniques.  
 Notably, other than the aforementioned immediate treatment options 
for clinically localized prostate cancer, active surveillance (careful 
observation/watchful waiting) is deemed appropriate for older men and for 
those with less aggressive tumours (American, 2012). 
 In the context of recurrent or advance prostate cancer, androgen-
deprivation therapy is the most common first line of treatment. This lowers the 
level of prostate-specific antigen initially but androgen-resistant tumours arise, 
which calls upon the need for secondary hormonal therapies. These therapies 
block androgen receptors or decrease the adrenal production of androgens. 
Nonetheless, despite initial success, these patients eventually progress under 
most circumstances. 
 Patients with such progression of disease would then need to undergo 
chemotherapy. Until 2004, mitoxantrone and prednisone were approved on the 
basis of an improvement in quality of life but no significant improvement in 
overall survival was observed. 
 Recent studies have postulated the concept of androgen receptor (AR) 
signaling as a mechanism of growth even in androgen-independent disease 
state. Thus, novel targeted therapies such as abivaterone which works by 
blocking androgen synthesis, is presently in phase III trials. Hsp90 chaperone 
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inhibitors that induce protein degradation are also strategies being tested to 
target the AR protein. 
 Another treatment option for androgen-independent prostate cancer is 
a cancer vaccine known as sipuleucel-T (Provenge). Special immune cells are 
being removed and exposed to prostate proteins, subsequently reinfused back 
to attack the cancer cells (American, 2012).  
 Metastatic prostate cancer remains a challenge today. Despite classic 
therapeutic options, modifications and especially novel targeted therapies are 
necessary to improve treatment efficacy. 
 
1.1.8 Risk factors for prostate cancer 
 Age is considered to be the strongest risk factor for prostate cancer 
incidence and mortality. Though some may assume that younger men have 
worse prognosis, studies have shown that young age is not necessarily 
associated with negative outcomes (Magheli et al., 2007). 
Family history of prostate cancer has shown to increase the risk of 
prostate cancer mortality. Under this context, the risk is more than doubled. 
This risk is increased with the number of first-degree affected relatives and is 
further worsened if these relatives are diagnosed at a young age. Data suggests 
that fatal prostate cancer may be caused by genetic predisposition of familial 
prostate cancer (Hemminki, 2012). Genetic studies reveal that hereditary 
prostate cancer gene 1 (HPCG) may correlate with an increased risk of 
prostate cancer. Mutations in BRCA1 or BRCA2 genes may also increase the 
risk. Other genes demonstrated to have an association with prostate cancer 
include the RNASEL gene, SRD5A2 and the androgen receptor gene. RNASEL 
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is believed to regulate cellular proliferation and apoptosis. SRD5A2 catalyzes 
the conversion of testosterone to the active dihydrotestosterone (Crawford, 
2003). 
A diet high in the consumption of red meat or high-fat dairy products 
appears to impose a greater risk (Marshall, 2012). The enzyme responsible for 
the peroxisomal oxidation of these fatty acids is upregulated in prostate 
cancer. As oxidation produces hydrogen peroxide, it may cause oxidative 
stress to the prostate genome. Food rich in lycopenes such as tomatoes and 
watermelon may help to reduce the risk (Giovannucci, 2005). The western 
lifestyle that contributes to obesity may cause a greater risk of high-grade 
aggressive prostate cancer. In this instance, obesity is correlated with an 
increased risk of Type 2 diabetes, a condition characterized by high insulin 
and insulin-like growth factor-1 (IGF-1), of which high levels would promote 
the occurrence of cancer (Calle et al., 2003; McGreevy et al., 2007). An 
increased level of androgen and estrogen/androgen ratio may also promote 
prostate cancer development.  
Currently, African-American men have a 1.6 fold higher risk of 
diagnosis and 2.5 fold greater risk of death as compared to the Whites. The 
Asians are less likely to suffer from prostate cancer than the Caucasians. 
However, if these members were to blend into the westernized lifestyle, the 







1.1.9 Prognostic factors for prostate cancer 
 Knowledge of prognostic factors has broad applications such as the 
selection of treatment plans and prediction of outcome in individual patients. 
Gleason grading as described in the previous section, is recommended as the 
international standard for prostate cancer grading and is a valuable prognostic 
factor. The Gleason score assigned upon radical prostatectomy is in fact the 
most powerful predictor of progression following radical prostatectomy 
(Bostwick, 1994). 
 The extent of tumour involvement (tumour volume) reports the linear 
length of cancer in mm. In this study’s patient data for immunohistochemistry, 
the longest single length of tumour is being reported. It is a parameter shown 
to correlate with Gleason score, surgical margins and significant in predicting 
biochemical recurrence. 
 Perineural invasion is defined as the presence of prostate cancer along, 
around or within a nerve. It is one of the major mechanisms by which prostate 
cancer cells metastasize out of the gland. Studies have indicated that its 
presence correlates with extraprostatic extension (Anderson et al., 1998; 
Quinn et al., 2003; Vargas et al., 1999) despite not being an independent 
predictor of prognosis. However, it may predict lymph node metastasis and 
post-surgical progression (Sebo et al., 2001). 
 Lymphovascular invasion consists of tumour cells found within the 
endothelial-lined spaces. Studies in radical prostatectomy specimens have 
demonstrated a correlation of lymphovascular invasion with lymph node 
metastasis and biochemical recurrence (Ito et al., 2003; Shariat et al., 2004).  
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 Clinical staging of prostate cancer is usually performed during the 
initial evaluation of a patient before treatment. The AJCC has published a 
revised TNM staging system (AJCC, 2009) for prostate carcinoma in 2009 as 
illustrated in the following table (Table 1.3): 
 
Table 1.3 TNM staging system for carcinoma of the prostate (AJCC) 
Pathologic (pT) primary tumour: 
pT2 (Organ confined) 
- T2a: Tumour involves half of a lobe or less 
- T2b: More than half of a lobe involved but 
not both lobes 
- T2c: Tumour involves both lobes 
pT3: Extraprostatic extension 
- T3a: Extraprostatic extension 
- T3b: Seminal vesicle extension 
pT4: Invasion of bladder, rectum 
* There is no pathologic T1 category 
 
Clinical (cT) primary tumour: 
TX: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
T1: Tumour not palpable or visible by imaging 
- T1a: Tumour incidental histologic finding in 
5% or less of resected tissue 
- T1b: Tumour incidental histologic finding in 
more than 5% of resected tissue 
- T1c: Tumour found in one or both lobes by 
needle biopsy but not palpable or visible by 
imaging 
T2: Tumour confined within the prostate 
- T2a: Tumour involves half of a lobe or less 
- T2b: More than half of a lobe involved but 
not both lobes 
- T2c: Tumour involves both lobes 
T3: Tumour extends through the prostatic 
capsule 
- T3a: Extracapsular extension (unilateral or 
bilateral) 
- T3b: Seminal vesicle invasion 
T4: Tumour is fixed or invades adjacent 
structures other than the seminal vesicles, 
bladder neck and rectum etc. 
 
Regional lymph nodes (N): 
NX: Regional lymph nodes 
cannot be assessed 
N0: No regional lymph 
node metastasis 
N1: Metastasis in regional 
lymph node or nodes 
 
Distant metastasis (M): 
MX: Distant metastasis 
cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
- M1a: Non-regional 
lymph node(s) 
- M1b: Bone(s) 




 As the glandular prostate lacks a well-defined capsule, the term 
‘extraprostatic extension’ (EPE) replaces ‘capsular penetration’ to describe 
tumour that has extended out of the prostate into the periprostatic soft tissue 
(Mazzucchelli et al., 2002). In the context where periprostatic fat involvement 
is absent, EPE may also be reported when the tumour involves perineural 
spaces in the neurovascular bundles. The degree of EPE carries prognostic 
importance and as such, efforts have been made to define it as focal or non-
focal (extensive) (Montironi R., 2007).  
 Another significant prognostic indicator, seminal vesicle invasion, is 
defined as cancer invading into the muscular coat of the seminal vesicle 
(Ohori et al., 1993). In most cases, it occurs in glands with EPE (Epstein et al., 
2000). 
 Notably, failure to eradicate EPE of the tumour can lead to positive 
surgical margins, a prognostic marker of prostate cancer progression. Patients 
with positive margins have a significantly increased risk of progression. A 
positive resection margin occurs when tumour cells touch the ink at the 
margin. 
 Despite the efficacy of these clinical factors in guiding treatment 
decisions, clinical heterogeneity remains and molecular factors are explored to 
better predict the risk of progression and facilitate treatment planning. The 







Table 1.4 Potential biomarkers of prostate cancer prognosis (modified from 
Martin et al., 2012) 
 
Biomarker Mode of action Summary 
AKT/PTEN Partake in 
phosphoinositol 3-
kinase pathway 
AKT in its unaltered and active 
forms are demonstrated to have 
prognostic value in determining 
biochemical recurrence (Ayala et al., 
2004; Li et al., 2009). Loss of PTEN 
is related to a greater risk of 
recurrence, biochemical failure, high 
Gleason score and advanced 
pathological stage (Halvorsen et al., 
2003; McMenamin et al., 1999). 
Androgen receptor Transcription factor 
mediating cell growth 
Results from radical prostatectomy 
series help to predict prostate cancer 
recurrence (Shukla-Dave et al., 
2009). 
BCL2 Regulates apoptosis A prognostic factor associated with 
higher risk of mortality and 
recurrence following RP and 
treatment failure for patients 
receiving radiation therapy (Bauer et 
al., 1996; Concato et al., 2009; 
Scherr et al., 1999). 
EZH2 Gene-silencing protein High expression is correlated with 
poor prognosis in localized prostate 
cancer (Varambally et al., 2002). 
Ki67 Nuclear antigen 
denoting cellular 
proliferation 
Found to be prognostic for distant 
metastasis and mortality following 
radiation therapy as well as a marker 
of recurrence after RP (Bettencourt 
et al., 1996; Pollack et al., 2004). 
p16/INK4A Tumour suppressor 
gene regulating cell 
cycle 
Overexpression is related to an 
increased PSA relapse after radical 
prostatectomy and a general poor 
prognosis (Lee et al., 1999). 
p21/WAF1/CIP1 Regulates G1 of cell 
cycle 
An increased staining is related to an 
unfavourable prognosis (Aaltomaa et 
al., 1999). 
p27/KIP1 Inhibits cell cycle Decreased expression is associated 
with an increased risk of seminal 
vesicle invasion, recurrence and a 
higher pathological stage (Halvorsen 
et al., 2003; Kuczyk and Machtens, 
1999). 
p53 Tumour suppressor 
gene associated with 
DNA repair 
Nuclear expression independently 
predicts cancer progression after RP 





1.1.10 Current challenges 
 Prostate cancer is responsible for 29% of all cancers in men and is the 
second highest cause of cancer death amongst men of all races (Jemal et al., 
2010; Siegel et al., 2011). In 2012, it was estimated to be the most frequently 
diagnosed cancer and the second leading cause of cancer morbidity in 
American men (American, 2012). 
 PSA screening has largely increased prostate cancer awareness. 
However, due to the heterogeneity of the disease and the unspecific nature of 
PSA test, a huge disparity occurs between the incidence and mortality of 
prostate cancer. In fact, increased incidence has been largely associated with 
clinically insignificant prostate cancer (would not progress to cause death) 
(Barqawi et al., 2012). These issues in turn pose challenges to the physicians 
in terms of devising appropriate treatment regimens and disease 
prognostication. Under or overtreatment may occur which results in side 
effects that put the patient’s quality of life at risk (Barqawi et al., 2012). 
 Thompson et al. in 2005 has demonstrated that no single PSA cutoff 
yields both high sensitivity and specificity (Thompson et al., 2005). PSA 
testing continues to detect prostate cancer at its clinically insignificant stages. 
Thus, this may result in overdiagnosis and overtreatment inevitably (Barqawi 
et al., 2012). 
 Active surveillance (AS) may seem most appropriate to resolve the 
overtreatment issue. Nonetheless, there is a lack of consensus on the inclusion 
criteria for AS (Penson, 2009). The need to better distinguish between the 
aggressive and non-aggressive forms of prostate cancer is hence paramount. In 
order to do so, it is important to study diagnostic markers to better stratify the 
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patients. Molecular biomarkers may offer better therapeutic options. 
Additionally, studying the molecular mechanisms behind prostate cancer may 
enable us to better understand its heterogeneity and hence improve the 
























1.2 Glycosaminoglycans and Proteoglycans 
1.2.1 Structural composition 
 Glycosaminoglycans (GAG) are unbranched polysaccharides 
comprising the repeating disaccharides of uronic acids (D-glucuronic acid or 
L-iduronic acid) and amino sugars (D-glucosamine or D-galactosamine). 
There are four major classes of GAG being identified, namely heparan 
sulphate, chondroitin/dermatan sulphate, keratan sulphate and hyaluronan. 
These different types of GAG chains, with the exception of hyaluronan, are 
attached to core proteins to form structurally diverse proteoglycans (Figure 
1.1).  
The proteoglycans are firstly biosynthesized in the rough endoplasmic 
reticulum where the synthesized core proteins are subsequently transported to 
the Golgi apparatus for the addition of GAG chains (Yung and Chan, 2007). 
Importantly, the different GAG chain compositions determine the various 
classes of proteoglycans (Gandhi and Mancera, 2008; Yip et al., 2006). 
However, these compositions are not necessarily homogenous and more than 
one type of GAG may be found attached to a proteoglycan core protein. For 
example, syndecan-1 consists of both heparan and chondroitin sulphate chains. 
Proteoglycans can in turn be classified based on their protein core amino acid 
homology as well as their location (cell surface, basement membrane or 




Figure 1.1 Structure of glycosaminoglycans and proteoglycans 
 
1.2.2 Chondroitin/dermatan sulphate, keratan sulphate and hyaluronan 
 Chondroitin sulphate (CS) comprises the repeating disaccharide units of 
N-acetylgalactosamine and glucuronic acid (iduronic acid in the case of 
dermatan sulphate). CS is further subclassified into 5 types based on their 
sulphation patterns; CS-A (GlcA-GalNAc-4-O-sulphate), CS-C (GlcA-
GalNAc-6-O-sulphate), CS-D [GlcA(2-O-sulphate)-GalNAc(6-O-sulphate)] 
or CS-E [GlcA-GalNAc-(4,6)-O-disulphate]. Dermatan sulphate, formerly 
designated as CS-B, consists of iduronic acid moieties. CS has been found to 
regulate the ECM assembly as well as cellular proliferation, migration, 
invasion, adhesion and apoptosis (Theocharis et al., 2006). It is also 
upregulated in cancers such as the prostate, breast, gastric and colon (Afratis 
et al., 2012; Asimakopoulou et al., 2008).  
 Keratan sulphate, in comparison to CS and heparan sulphate, has a 
simpler structure consisting of repeating galactose and N-acetylglucosamine 
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units. Studies have shown its importance in maintaining the structure and 
arrangement of collagen fibrils in the corneal stroma (Quantock et al., 2010; 
Rada et al., 1993).  
 Hyaluronan is a non-sulphated glycosaminoglycan consisting of 
repeating glucuronic and N-acetylglucosamine units. Hyaluronan binds to 
CD44, hyaluronan-mediated motility receptor RHAMM and Toll-like 
receptors to elicit cellular growth (Turley et al., 2002). Due to its interactions 
with CD44 and RHAMM, hyaluronan has been implicated recently in cancer 
progression (Afratis et al., 2012; Kouvidi et al., 2011). 
 As the detailed study of these 3 classes of GAG is beyond the scope of 
this project, emphasis would be placed on heparan sulphate and HS3ST3B1 (a 
heparan sulphate biosynthetic enzyme that is the molecule of interest in this 
study). 
 
1.2.3 Heparan sulphate - biosynthesis and 3-O-sulphation 
The biosynthesis of heparan sulphate involves formation of a 
polysaccharide backbone with posttranslational sulphation and epimerization 
modifications (Liu et al., 1999). This polysaccharide backbone consists of 
approximately 100 repeating disaccharide units of glucuronic acid (GlcA) and 
N-acetylated glucosamine (GlcNAc) residues attached to the tetrasaccharide 
(xylose-galactose-galactose-glucuronic acid) linkage region (Lind et al., 
1993). Synthesis of heparan sulphate is firstly initiated by xylosyltransferase 
to cause the formation of the tetrasaccharide linkage, a process catalysed by 
transferases that add the sugar residues sequentially (Esko and Lindahl, 2001). 
The linkage region subsequently undergoes phosphorylation at C2 of xylose 
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and sulphation at C4 or C6 of the galactose residues. After the linkage region 
is assembled, GlcNAc transferase adds GlcNAc unit to commit the chain 
polymerisation towards the synthesis of heparan sulphate (Esko and Lindahl, 
2001).  
Polymerisation then occurs by the alternate addition of GlcA and 
GlcNAc residues, a process catalysed by the exostosin family of tumour 
suppressors. EXT1 and EXT2, key components of the HS-polymerase 
complex, are mainly responsible for this elongation process (Duncan et al., 
2001). Interestingly, Nigro et al. have shown that the elongation of heparan 
sulphate can be inhibited by 4-F-GlcNAc, which truncates the growing chain 
at the nonreducing terminus (Nigro et al., 2009). As the chain polymerises, a 
series of modifications occur (Figure 1.2). Heparan sulphate N-deacetylase/N-
sulphotransferase (NDST) alters GlcNAc to form N-sulphated glucosamine 
(GlcNS) (Orellana et al., 1994). Heparan sulphate C5 epimerase subsequently 
converts GlcA to iduronic acid (IdoA) within the polysaccharide (Li et al., 
1997). O-sulphation reactions can occur at C2 of GlcA and IdoA, C3 of GlcN 
as well as C6 of GlcNAc and GlcNS residues (Esko and Lindahl, 2001). 
Heparan sulphate biosynthetic enzymes are present in multiple 
isoforms having different substrate specificities (Rosenberg et al., 1997). 3-
OST-1, the enzyme responsible for converting non-anticoagulant heparan 
sulphate to anticoagulant heparan sulphate, only sulphates glucosamine in 
GlcA-GlcNS±6S (Liu et al., 1999). 
3-OST-3A was found to catalyse the 3-O-sulphation of glucosamine in 
IdoA2S-GlcNS and heparan sulphate modified by 3-OST-3A does not contain 
anticoagulant activity (Liu et al., 1999).  
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3-OST-3B, similar to 3-OST-3A, transfers sulphate from PAPS to the 
3-OH position of the glucosamine residue. Both sulphate an identical 
disaccharide (Liu et al., 1999). 
According to our knowledge, recent studies have demonstrated 
potential biological functions of 3-OST-3B (HS3ST3B1). HS3ST3B1 has 
shown to inhibit Hepatitis B virus replication (Zhang et al., 2010). Another 
study suggests the ability of HS3ST3B1 in influencing malaria, specifically P. 
falciparum parasitaemia in humans (Atkinson et al., 2012). Nonetheless, the 
role of HS3ST3B1 in disease pathogenesis remains elusive and that there has 
been no studies conducted in relation to its functions in cancer. Given that 
recent studies have shed some light into HS3ST3B1 and its potential influence 
in disease pathogenesis, HS3ST3B1 warrants further investigation in order to 








Figure 1.2 Biosynthesis of heparan sulphate 3-O-sulphotransferase isoforms. 
This figure highlights the enzymes involved in the chain initiation, 
polymerisation and modification of HS3ST biosynthesis. 
 
1.2.4 The sulphatases – enzymatic remodeling of heparan sulphate  
Human sulphatase 1 (hSulf-1) is an extracellular heparan sulphate 6-0-
endosulphatase that desulphates cell surface heparan sulphate 
glycosaminoglycans (Lai et al., 2008). It was shown to be inactivated in 
various cancers such as the ovarian, breast, renal, pancreatic as well as head 
and neck squamous cell carcinomas (Ji et al., 2011). 
 hSulf-1 has also been found to inhibit the phosphorylation of kinases 
such as the EGFR, ERK and AKT, thereby inhibiting these downstream 
signaling pathways. The loss of hSulf-1 is thus associated with an 
upregulation of growth factor signaling (Lai et al., 2003; Lai et al., 2006; 
Narita et al., 2006).  
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 Aside from its antiproliferation effect, hSulf-1 was shown to suppress 
angiogenesis by inhibiting the phosphorylation of VEGFR-2 in ovarian and 
hepatocellular cancer cells (Ji et al., 2011). 
 
1.2.5 Heparan sulphate in cellular physiology 
It has been shown that heparan sulphate is capable of binding to 
various proteins to partake in the functions of cellular adhesion, growth, 
differentiation and anti-coagulation (Gandhi and Mancera, 2008). Couchman 
and Woods demonstrated that HSPGs bind to fibronectin to elicit the 
formation of focal adhesions (Couchman et al., 2001). Cell surface HS also 
acts as a co-receptor to bind to fibroblast growth factors and transfer them to 
their receptors (Gallagher, 2012). 
Additionally, HS regulates innate and acquired immunity via its 
interaction with interferon gamma. Similarly, HS functions as a means of 
attachment on cell surfaces of vascular tissues to interact with chemokines at 
sites of inflammation (Gallagher, 2012). In the context of cellular 
differentiation and embryogenesis, HS aids in setting up diffusion gradients of 
morphogenic proteins such as Hedgehog and Bone Morphogenic Protein 
(Lindahl and Li, 2009). Furthermore, HS catalyses enzymes involved in blood 
coagulation and lipid metabolism (Bishop et al., 2007).  
Such diverse interactions of HS in various microenvironments cause it 






1.2.6 Heparan sulphate in cancer biology 
 Cell surface and extracellular matrix heparan sulphate is capable of 
regulating cellular transformation, growth, metastasis and invasion. The pro- 
and anticancer properties of heparan sulphate can be attributed to its structural 
diversity, resulting in varied interactions with other molecular factors to cause 
contrasting cellular behaviours that are dependent on the context of the tumour 
microenvironment (Sasisekharan et al., 2002).  
Perlecan, a HSPG containing several post-translational modifications, 
possesses pro- and anti-angiogenic activities. Its inhibition can cause a 
suppression of angiogenesis in human colon carcinoma and hepatoblastoma 
xenografts. This is in marked contrast to the anti-angiogenic activity of 
endorepellin (C-terminal fragment of perlecan), in which its delivery to mice 
squamous cell and lung tumour xenografts reduced angiogenesis and tumour 
growth (Iozzo and Sanderson, 2011; Stringer, 2006). 
Syndecans, proteoglycans bearing predominantly HSGAG chains, are 
involved in breast carcinoma, haematological malignancies, lung carcinoma, 
osteosarcoma and colon carcinoma. Syndecans have been associated with 
tumour invasiveness, metastasis and cellular adhesion (Iozzo and Sanderson, 
2011; Sasisekharan et al., 2002). 
Glypicans, another HSPG, have been studied extensively to regulate 
cancer growth in melanoma as well as cancers of the breast, colon, liver, lung, 






1.2.7 Heparan sulphate in prostate cancer 
Heparan sulphate has been documented to participate in various 
functions in the context of prostate cancer. These functions encompass the 
aspects of cancer phenotypes – cellular proliferation, migration, invasion and 
adhesion.  
Hartman et al. engineered electrospun PCL-based scaffolds with 
perlecan domain IV (PlnDIV) peptide and found that the presence of PlnDIV 
may facilitate cellular growth by enhancing matrix adhesion. They had also 
observed an increased migratory potential of C4-2B cells to invade the 
modified scaffold. A significant reduction in the expression of tight junction 
protein in PlnDIV modified scaffolds was observed. As studies have indicated 
E-cadherins’ (tight junction protein) function in suppressing tumour cells’ 
invasiveness, Hartman et al.’s study postulates PlnDIV’s role in tumour 
progression (Hartman et al., 2010). In a similar study involving Perlecan, 
Perlecan inhibition was found to reduce cellular proliferation in both 
androgen-dependent and –independent tumour cells (Datta et al., 2006). 
Perlecan has been found to act as a co-receptor enabling the delivery of 
heparin binding growth factors (HBGFs) such as FGF-2 via 
glycosaminoglycans in domains I and V. Savorè et al. demonstrated that 
perlecan knockdown cells responded poorly to FGF-2. The in vivo study of 
mice bearing perlecan knockdown prostate cancer cells revealed a reduced 
growth rate (Savore et al., 2005). 
Other studies have similarly revealed the ability of perlecan and 
syndecan-1 in regulating tumour growth and proliferation of prostate cancer 
cells (Brimo et al., 2010; Datta et al., 2006; Savore et al., 2005; Shimada et al., 
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2009). In fact, the extent and degree of sulphation have been demonstrated to 
contribute to heparan sulphate’s ability to bind growth factors such as FGF, 
VEGF and hepatocyte growth factor (Ashikari-Hada et al., 2004; Flaumenhaft 
et al., 1990; Kreuger et al., 2006; Ornitz et al., 1992).  
Additionally, perlecan promotes FGF-2 receptor binding affinity and 
angiogenesis (Hardingham and Fosang, 1992). Moreover, the binding of 
perlecan to HBGFs protects angiogenic growth factors from proteolysis, thus 
facilitating malignant cell growth (Saksela et al., 1988; Whitelock et al., 
1996). It has thus been hypothesized by Iozzo that perlecan functions as a 
scaffold for new capillary formation (Iozzo, 1998). Perlecan as studied and 
concluded by Savorè et al., plays an essential role in delivering FGF-2 to 
effect in cellular growth and culminate in angiogenesis (Savore et al., 2005; 
Zhou et al., 2004). Ferguson et al. has found that the expression of heparan 
sulphate 2-O-sulphotransferase (2OST) is upregulated as prostate cancer cells 
increase in metastatic potential. These studies point towards the role of 
heparan sulphate in promoting prostate metastasis (Ferguson and Datta, 2011).  
The multifaceted functions of HSPGs have enabled them to regulate 
various pathways. Focal adhesion proteins are critical complexes connecting 
the cell cytoskeleton and the ECM. In the study by Hartman et al., it was 
observed that the presence of PlnDIV peptide activated focal adhesion kinase 
(FAK) phosphorylation on tyrosine 397. FAK phosphorylation is in fact a key 
signalling event capable of enhancing cellular proliferation and migration 
(Hartman et al., 2010). In a complementary study by Datta et al., Perlecan has 
been demonstrated to directly modulate Sonic Hedgehog (SHH) signalling.  
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Notably, Ferguson et al. have shown that intertwined in this perlecan-
SHH signaling is the requirement of 2OST. Optimal SHH, FGF and TGFß 
signaling in highly metastatic prostate cancer C4-2B cells is only achievable 
with 2OST (Ferguson and Datta, 2011). A few other studies postulated further 
that SHH signaling is sufficient for the growth and metastasis of advanced 
prostate cancer cells (Karhadkar et al., 2004; Sanchez et al., 2004; Sheng et 
al., 2004).  
In fact, more than a decade ago, Aviezer et al. have studied that FGF2 
binds to the heparan sulphate chains of perlecan to promote angiogenesis. This 
complex results in a higher affinity binding to FGF receptor and thence a more 
sensitive growth factor signaling (Aviezer et al., 1994). Furthermore, 
sulphation and epimerization of heparan sulphate chains have been shown to 
affect growth factor binding affinity (Lin, 2004). This highlights the 
importance of heparan sulphate glycosaminoglycans in modulating prostate 
cancer signaling pathways. 
We understand too, from Wu et al.’s study, the importance of 
investigating the critical switch of malignancy from androgen-dependent to 
androgen-independent prostate cancer. Abnormal expression of fibroblast 
growth factor receptor-1 (FGFR1) has been shown to correlate with tumour 
progression. In some models of prostate cancer, the hallmark of malignant 
progression is characterised by the loss of FGFR2 and subsequent gain in 
activity of FGFR1. Wu et al. had successfully identified syndecan-1, a HSPG 
containing heparan sulphate chains, to form an integral part of the tripartite 
FGFR1 complex. This study is thence postulative of syndecan-1’s plausible 
role in the pivotal switch of malignancy. The researchers proposed that the HS 
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chains of syndecan-1 are capable of altering FGFR isotypes and when the 
composition/sulphation pattern changes to obliterate FGFR1-binding motifs, 
FGF-independence occurs (Wu et al., 2001).  
This is in support of previous studies illustrating the requirement of 
heparan sulphate chains for sequestering and binding of FGF-2 to its receptor 
within the ECM (Bernfield and Hooper, 1991; Roghani et al., 1994). 
Specifically, both the 2-O-sulphate of iduronic acid and 6-O-sulphate groups 
of N-sulphated glucosamine are needed for FGF-2’s mitogenic activity. 
An intriguing aspect of syndecans is illustrated aptly by Hu et al.’s 
study whose findings proposed the critical role of syndecan-1 in suppressing 
the phosphorylation of PDK1/Akt/Bad to mediate n-3 PUFA-induced 
apoptosis in prostate cancer (Hu et al., 2010). Hu et al. has further clarified the 
tumour suppressive role to be attributed to syndecan-1’s ectodomain. This is 
in contrast to Wu et al.’s findings of syndecan-1 as a tumour promoter.  
 In another study by Shimada et al., the researchers demonstrated that 
knockdown of syndecan-1 in DU145 and PC-3 (androgen independent 
prostate cancer cell lines) resulted in a downregulation of NOX2 and VEGF 
protein expression, suggesting a possible mechanism involving NOX2-
dependent ROS signaling for hormone-insensitive prostate malignancy 
(Shimada et al., 2009). 
A key step in tumourigenesis is epithelial-mesenchymal transition 
(EMT). During this process where cancer cells transform from the epithelial to 
mesenchymal phenotype, proteoglycan expression changes. Contreras et al. 
have observed a subcellular redistribution of syndecans-1 and -2 when 
comparing between patient samples of high (>7) and low (<7) Gleason scores, 
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suggestive of syndecan’s participation in prostate cancer progression and 
possibly the EMT process (Contreras et al., 2010). Another study by 
Kiviniemi et al. managed to demonstrate an inverse correlation between 
syndecan-1 expression and Gleason grade, further ascertaining syndecan’s 
potential regulatory role in prostate cancer progression (Kiviniemi et al., 
2004). 
Do syndecans function then as tumour promoters or suppressors? Of 
noteworthy mention are the following studies which underlie different 
perspectives of syndecans. In contrast to Contreras et al.’s study showing a 
decrease in syndecan-1 and -2 staining observed along with higher Gleason 
score (Contreras et al., 2010), Popovic et al. illustrated a parallel relationship 
between syndecan-2 and adverse clinicopathological parameters such as 
higher Gleason score and extraprostatic extension (Popovic et al., 2010). 
Additionally, Shimada et al. highlighted syndecan-1’s role in promoting 
angiogenesis and the conversion to an androgen-independent state of prostate 
cancer (Shimada et al., 2009). This is supplemented by Amler et al.’s study of 
syndecan-1’s expression being upregulated during the androgen-independent 
state in the CWR22 prostate cancer model (Amler et al., 2000). In another 
study by Chen et al., syndecan-1’s expression correlated with a higher PSA 
recurrence rate in Gleason sum 7 prostate cancer (Chen et al., 2004). 
Zellweger et al.’s tissue microarray study also revealed an association between 
syndecan-1 and PSA recurrence (Zellweger et al., 2003). 
The study by Franzen et al. further highlights the diverse roles of 
syndecans. Syndecan-4 was found to interact with matrix protein CCN1 to 
support cellular adhesion and in turn promoting cellular growth. Tumour 
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necrosis factor-related apoptosis-inducing ligand (TRAIL) is capable of 
preferentially inducing apoptosis of cancer cells. Franzen et al.’s study has 
also revealed a potential dilemma in that CCN1 enhances TRAIL-induced 
apoptosis via interactions with integrins !vß3 and !6ß4 and syndecan-4 
(Franzen et al., 2009). 
Heparan sulphate glycosaminoglycans and proteoglycans, as evident in 
the above studies, are capable of interacting with various molecules to elicit 
signaling pathways. The following diagram (Figure 1.3) summarizes the 




Figure 1.3 Signaling pathways and molecules heparan sulphate may interact 
with to cause pro-tumourigenic cellular behaviour 
 
1.3 Summary of Teng (2010) study 
 This dissertation is an extension of Teng (2010) study which 
investigated the functions of chondroitin and heparan sulphate proteoglycans 
in prostate cancer. 
 Genome-wide expression profiling of prostate adenocarcinoma tissues 
revealed differential expression of CSGalNAcT-1, HS3ST3A1 and HS6ST2. 
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CSGalNAcT-1, a gene involved in chondroitin sulphate/dermatan sulphate 
synthesis, was silenced in PC-3 prostate cancer cells. This inhibited cellular 
proliferation and invasion. Furthermore, apoptosis was promoted via 
suppression of MAPRE-1, TPX2 and HIPK3. These results point to a potential 
role of CSGalNAcT-1 as a novel therapeutic target (Teng, 2010). 
Heparan sulphotransferases, HS3ST3A1 and HS6ST2, were silenced in 
RWPE-1 normal prostate epithelial cells. This led to an inhibition of cellular 
growth and motility. Importantly, at this juncture, it was found that HS3ST3B1 
was downregulated in both prostate cancer cell lines and adenocarcinoma 
tissues (Teng, 2010). 
 
1.4 Objectives of project 
 The identification of novel biomarkers and therapies can greatly 
facilitate the detection and treatment of prostate cancer. This would help 
enable a more accurate staging for subsequent patient stratification into the 
appropriate and improved treatment regimens. Hence, the objectives of this 
dissertation are to: 
1. Check the expression level of HS3ST3B1 in prostate cell lines by real-time 
polymerase chain reaction and subsequently determine its functional 
significance in prostate cancer cellular phenotypes using silencing RNAs.  
2. Examine the potential downstream genes upon downregulating HS3ST3B1 
via microarray analysis. 
3. Establish the application of HS3ST3B1 as a biomarker of prostate cancer 
progression by determining its expression level and pattern in prostate 
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cancer tissues via immunohistochemistry and subsequently determining 














Materials and Methods 
 
2.1 In vitro cell culture  
 
2.1.1    Cell lines 
 
Normal prostate epithelial RWPE-1 cell line and breast tumourigenic MDA-
MB-231 cell line were purchased from American Type Culture Collection 
(ATCC, Manassas, VA, USA). RWPE-1 was propagated in keratinocyte-
serum free medium, supplemented with 0.05mg/ml bovine pituitary extract 
and 5ng/ml recombinant epidermal growth factor (Invitrogen Corporation). 
MDA-MB-231 was maintained in RPMI-1640 (Sigma-Aldrich, USA) 
supplemented with 10% Fetal Bovine Serum (FBS) (Hyclone, Thermo Fisher 
Scientific Inc, Massachusetts, United States of America). Human prostate 
cancer cell lines LNCaP and PC-3 were kind gifts from A/P Marie Veronique 
Clement (Department of Biochemistry, National University of Singapore). 
HepG2, hepatocellular carcinoma cell line, was a kind gift from Prof Hooi 
Shing Chuan (Department of Physiology, National University of Singapore). 
Both LNCaP and PC-3 cells were cultured in RPMI-1640 supplemented with 
10% FBS, 2mM L-glutamine (Hyclone, Thermo Fisher Scientific Inc) and 
1mM sodium pyruvate (Hyclone, Thermo Fisher Scientific Inc). All cell lines 
were incubated in a humidified incubator at 370C under conditions of 5% CO2 
and 95% air atmosphere.  
 
2.1.2    Storage of cells 
 
The cryopreservation medium used for RWPE-1 is complete growth medium 
(see section 2.1.1) supplemented with 15% FBS and 10% dimethylsulfoxide 
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(DMSO) (Sigma-Aldrich, Missouri, United States of America). The 
cryopreservation medium used for LNCaP and PC-3 comprises of complete 
growth medium (see section 2.1.1) supplemented with 20% FBS and 5% 
DMSO. The cell suspensions were then stored at -800C freezer overnight to 
ensure gradual freezing before storing in liquid nitrogen. 
 
2.1.3    RNA extraction, cDNA synthesis and qPCR of prostate cell lines 
2.1.3.1    RNA extraction 
RNeasy Mini Kit (Qiagen, Hilden, Germany) was used to isolate total RNA 
from RWPE-1, LNCaP and PC-3 prostate cell lines following the 
manufacturer’s protocol. Cells cultured were completely washed twice with 
1! PBS and lysed with 350 "l buffer RLT containing 1% ß-ME. Cell lysates 
were then homogenized, mixed with one volume of 70% RNase-free ethanol 
and transferred into a RNeasy MiniElute spin column. Column was then 
centrifuged for 30s at 13, 200 rpm. In the following sequential order, 350 "l 
buffer RW1 and 500 "l buffer RPE were added to wash the column’s 
membrane. Eventually, the RNA was eluted with 32 "l of RNase-free water 
by centrifugation at 13, 200rpm. The RNA yield and purity were then 
determined, with satisfactory OD260:OD280 ratios between 1.8 and 2.1. 
 
2.1.3.2    cDNA synthesis 
1"g of total RNA was converted into cDNA using the SuperScript III First-
strand cDNA synthesis kit (Invitrogen Corporation) according to 
manufacturer’s protocol. In this process, random hexamer primer (50ng/"l), 
dNTP (10mM stock), 5! first strand reaction buffer, RNase inhibitor, 
Materials and Methods 
! $'!
SuperScript III reverse transcriptase and DEPC-treated H2O are required. 
Resultant cDNA was then diluted and stored until use. 
 
2.1.3.3    qPCR of prostate cell lines 
The cDNA was then used for real-time PCR using QuantiTect SYBR Green 
PCR Kit (Qiagen) on the Roche LightCycler 2 machine (Roche Diagnostics 
Corporation, Roche Applied Science). Primers used for real-time PCR are as 
shown in Table 2.1. Table 2.2 indicates the programme settings for qPCR. 
The reaction contains diluted cDNA, forward and reverse primers (each of 10 
"M stock), QuantiTect SYBR Green Master solution and DEPC-treated H2O. 
Cycle parameters consist of the following four programmes according to 
manufacturer’s protocol: denaturation of template cDNA, amplification of the 
target gene, melting curve analysis and cooling of rotor. 
 
2.1.4    Quantitative real time polymerase chain reaction (qRT-PCR) 
Intron-spanning primers were designed using Primer3 software 
(http://frodo.wi.mit.edu/) and their specificities were verified using nucleotide 
BLAST from the NCBI website (http://blast.ncbi.nlm.nih.gov). The following 
table consists of sequences of primers synthesized in this study (1st Base, 
Singapore).  
 
Table 2.1 Sequences of PCR primers synthesized 
Gene 
symbol 
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Table 2.2 Programme settings for qPCR 
Programme Temperature Duration Ramp rate Cycle(s) 
Initial activation 950C 15 min 200C/sec 1 
3-step cycling    45 
  Denaturation 940C 15 sec 200C/sec  
  Annealing 600C 25 sec 200C/sec!  
  Extension 720C 15 sec 200C/sec!  
Melting curve 950C 0 sec 200C/sec! 1 
 650C 15 sec 200C/sec!  
 950C 0 sec 0.10C/sec!  
Cooling 400C 30 sec 200C/sec! 1 
 
2.1.5    Gene expression analysis of qPCR data 
Threshold cycle (Ct) is the specific cycle number of which SYBR fluorescence 
signal in the sample exceeds the level of background noise to become 
exponential. 
Fold changes in gene expression were calculated as such: fold change = 2-##Ct, 
where ##Ct = (Ct, target - Ct, reference)treated - (Ct, target - Ct, reference)control.  
 
2.1.6    Gene silencing 
1.9 x 105 RWPE-1 cells were seeded and allowed to adhere overnight in 6-
well plates. 5"l of Oligofectamine transfection reagent (Invitrogen 
Corporation) and a final concentration of 15nM of HS3ST3B1 siRNA (Qiagen, 
Hilden, Germany) were added to each well. Complete growth medium with 
2% FBS was added 8 hours after transfection and transfection medium was 
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replaced with complete growth medium 24 hours post-transfection. The 
aforementioned was carried out similarly for OPN3 silencing, with the 
exception of a final concentration of 5nM of OPN3 siRNA (Qiagen, Hilden, 
Germany) being used. As for SULF1 siRNA (Ambion, Inc / Applied 
Biosystems) optimisation, various concentrations of siRNA were attempted. 
The sequences for the various siRNAs are listed in Tables 2.3 and 2.4. 
Silenced cells were harvested 48 hours post-transfection for ascertaining 
silencing efficiency and for cellular phenotypic assays. 
 
Table 2.3 Qiagen HS3ST3B1 and OPN3 siRNA sequences 















2.1.7    SULF1 silencing optimisation 
Aside from various siRNA concentrations attempted, SULF1 silencing was 
performed in MKN7 gastric cancer cells. 1.5 x 105 MKN7 cells were seeded 
and allowed to adhere overnight in 6-well plates. 4"l of DharmaFECT 1 
transfection reagent (Thermo Fisher Scientific, Massachusetts, United States 
of America) and a final concentration of 5nM of SULF1 siRNA (Ambion, Inc 
/ Applied Biosystems) were added to each well. Transfection medium was 
replaced with complete growth medium 24 hours post-transfection.  
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Table 2.4 Ambion SULF1 siRNA sequences 
















2.1.8 shRNA plasmid amplification   
Five sequences of shRNA plasmids were purchased from SABiosciences 
(SABiosciences, Qiagen, USA). These sequences of HS3ST3B1 and negative 
control shRNA are as shown in Table 2.5. 1 "L of each plasmid was 
transformed into 100 "l DH5$ competent E. coli cells. The bacterial culture 
was then spread to LB plates containing 100 "g/ml ampicillin (Sigma-Aldrich, 
USA) and incubated at 37ºC overnight. Following the incubation, colony-PCR 
was performed with T7 and SP6 as primers. Colonies were subsequently 
selected to grow in 5 ml of LB broth supplemented with 100 "g/ml ampicillin. 
Cultures were shook at 300 rpm at 37ºC for 16 hours. The following day, 
plasmids were extracted from the bacteria using the QIAprep Spin Miniprep 
kit (Qiagen, Hilden, Germany) and their concentrations were determined. 
 
Table 2.5 Qiagen HS3ST3B1 and negative control shRNA sequences 







Negative control ggaatctcattcgatgcatac 
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2.1.9 shRNA transfection   
Lipofectamine 2000 was used as the delivery reagent to transfect the shRNA 
plasmids into RWPE-1 cells. A day prior to transfection, 1 x 105 RWPE-1 
cells were seeded into each well of a 24-well plate to achieve a 90% cell 
confluency by the time of transfection. 0.4 "g shRNA and 1.2 µl 
Lipofectamine 2000 were each diluted in 50 "l of Opti-MEM I separately. 
These 2 mixtures were incubated at room temperature for 5 minutes. They 
were then combined gently and incubated for 20 minutes at room temperature 
to allow for plasmid-lipofectamine complex formation. 400 "l of RWPE-1 
complete growth medium was then added to the complex, from which a total 
volume of 400 "l was added to each well of RWPE-1 cells. The plate was then 
incubated in the 5% CO2, 37ºC humidified incubator for 4 hours before adding 
500 "l of complete growth medium supplemented with 5% FBS. The plate 
was then incubated overnight. The next morning, the transfection mixture was 
replaced with 500 "l of complete growth medium.  
48 hours after transfection, the cells were reseeded. Complete growth medium 
was supplemented with 300 "g/ml of G418 every 2-3 days for two weeks to 
select for the Neomycin-resistant cells. Two weeks after transfection, a single 
colony of cells was picked from each well and grown in a 24-well plate 
format. Upon reaching an approximate 80% cell confluency, the colonies were 
replated into 6-well plates. When confluent, the silencing efficiency was 
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2.1.10    Antibodies used 
Antibodies against HS3ST3B1 (rabbit polyclonal IgG and P-13, goat 
polyclonal IgG) were purchased from Abcam Inc, Cambridge, Massachusetts, 
United States of America and Santa Cruz Biotechnologies, California, United 
States of America respectively. %-actin monoclonal antibody, horseradish 
peroxidase conjugated anti-mouse IgG secondary antibody was purchased 
from Sigma-Aldrich, Missouri, United States of America. Polyclonal, 
horseradish peroxidase conjugated anti-goat IgG secondary antibody was 
purchased from Abcam Inc, Cambridge, Massachusetts, United States of 
America. Alexa-Fluor 488 conjugated anti-rabbit immunoglobulins secondary 
antibody was purchased from Invitrogen Corporation, California, United 
States of America. 
 
2.1.11   Western blot – Denaturing and non-denaturing methodologies 
2.1.11.1 Extraction of protein 
After 48-hour post HS3ST3B1 silencing, RWPE-1 cells were lysed using M-
PER® Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA). 
Protein supernatant was collected and stored at -800C until use. The 
concentration of the protein was determined using the BCA protein assay kit 
(Pierce, Rockford, IL, USA) according to manufacturer’s protocol. 
 
2.1.11.2 Preparation of resolving gel 
Resolving gel (10%) mixture was prepared using N-N-N’-N’-
Tetramethylethylendiamin (TEMED) and ammonium persulfate (APS) (Bio-
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Rad, Hercules, CA, USA). Isopropanol was overlaid on the gel and it was then 
allowed to polymerize for at least 30 minutes. 
 
2.1.11.3 Preparation of stacking gel 
The overlaying isopropanol was poured off and the mixture of stacking gel 
(10%) was added on top. Teflon comb was then inserted and subsequently 
removed after 30 minutes of gel polymerization. 
 
2.1.11.4 Separation and eventual visualization of proteins 
Proteins were resolved by SDS-PAGE and subsequently semi-dry transferred 
onto polyvinylidene difluoride membrane (Immun-Blot PVDF membrane, 
Bio-Rad Laboratories, California, United States of America). 40 "g of 
HS3ST3B1 silenced and scrambled negative control protein samples were 
used for the experiment. After SDS-PAGE, protein transfer was run for 60 
minutes at 15 volts. 
The membranes were then blocked in Tris-buffered saline containing 0.2% 
Tween 20 (Bio-Rad Laboratories) and 5% fat-free dry milk (Bio-Rad 
Laboratories). The blot was then incubated with the primary antibody 
overnight and then the horseradish peroxidase-conjugated secondary antibody. 
Chemiluminescence detection using SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Fisher Scientific) was employed to visualise the 
proteins. 
Similar to the aforementioned denaturing methodology, the non-denaturing 
format was carried out by preparing native gels and protein samples without 
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SDS and %-mercaptoethanol. The samples were then electrophoresed at 100V 
for 3 hours and subsequently wet transferred onto PVDF membrane.  
This non-denaturing format was performed as part of the optimization process. 
The proteins were eventually resolved using the denaturing methodology. 
 
2.1.11.5 Densitometric analysis of the band intensity 
The protein bands were scanned with a densitometer (Imaging Densitometer, 
Model GS-710, Bio-Rad, CA, USA) and their intensities measured with 
Quantity-one Image Analysis software (Bio-Rad, version 2012_001). The 
relative ratio of the band intensity to ß-actin was then calculated. 
 
2.1.12    Migration assay 
Cell migration assay was performed using Transwell Inserts (Corning 
Incorporated, New York, United States of America) of 6.5mm diameter and 
polycarbonated membrane of 8.0"m pore size. These inserts and the 24-well 
plate were hydrated with serum-free medium at 4°C overnight to improve cell 
attachment. The plate was subsequently incubated at 37°C for 2 hours with 
5% CO2.  
0.6ml of 20% FBS supplemented complete growth medium was added to the 
lower chamber. 2 x 104 RWPE-1 cells resuspended in 0.2ml serum-free 
medium were added to the inside of the Transwell inserts. Migration of the 
cells was allowed to occur for 24 hours at 370C with 5% CO2. The medium 
was then carefully removed from the upper and lower chambers of the inserts 
which were subsequently washed with 1X PBS and fixed with 0.6ml of 4% 
paraformaldehyde for 10 minutes. The inserts were rinsed with 1X PBS again 
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and left to air dry, thereupon stained with 0.6ml of aqueous crystal violet 
(0.5% w/v) for 30 minutes. The excess stain was washed out by immersing the 
inserts in a beaker of clean tap water. A cotton swab was used to clean the 
insides of the inserts in order to remove the unmigrated/uninvaded cells. The 
inserts were then air-dried and viewed under a microscope (Nikon SMZ 
1500). Five different field views of each insert were taken and the 
migrated/invaded cells were manually counted. 
 
2.1.13    Invasion assay 
BD BioCoatTM MatrigelTM Invasion Chambers (BD Biosciences, California, 
United States of America) were used for conducting the invasion assay. The 
Falcon Cell Culture Inserts contain an 8.0 "m pore sized polyethylene 
terephthalate (PET) membrane with a thin layer of Matrigel Basement 
Membrane Matrix. The Matrigel Matrix functions as a reconstituted basement 
membrane to block non-invasive cells from migrating through. In contrast, 
invasive cells are able to detach themselves from and invade through the 
Matrigel Matrix and the 8.0 "m membrane pores. The inserts were first 
hydrated overnight at 40C by adding serum-free medium to the 24-well plate 
wells and the inserts. The plate was then incubated for 2 hours at 370C with 
5% CO2 prior to the start of the invasion proper to improve cell attachment. 
0.5ml of 20% FBS supplemented complete growth medium was added to the 
lower chamber. 2 x 104 RWPE-1 cells resuspended in 0.5ml of serum-free 
medium were added to the inside of the inserts. Invasion of the cells was 
allowed to occur at 370C with 5% CO2 for 24 hours. Staining and counting of 
the invaded cells were performed as in Section 2.1.8, Migration assay. 
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2.1.14    Proliferation assay 
Proliferation assay was performed using the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) (Promega Corporation, Madison, 
Wisconsin, USA) according to manufacturer’s protocol. The CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS) contains a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium, inner salt; MTS] 
which is bioreduced by NADPH or NADH produced by metabolically active 
cells via mitochondrial dehydrogenase into a coloured formazan product. The 
quantity of formazan product is directly proportional to the number of viable 
living cells. 
 
2.1.15    Adhesion assay 
2 x 104 transfected RWPE-1 cells were seeded into pre-collagen type I-coated 
(BD Biosciences) and fibronectin-coated (BD Biosciences) 96-well plates. 
The cells were then incubated at 370C with 5% CO2 for 30 minutes. 
Unadhered cells were removed and washed twice with 1X PBS. Unwashed 
wells of cells were used as loading controls. Thereafter, CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (MTS) (Promega Corporation) was 
carried out to quantify the number of cells that adhered to collagen type I and 
fibronectin substrates. 
 
2.1.16    HS3ST3B1 silenced microarray analysis 
Total RNA was extracted from HS3ST3B1 silenced and scrambled negative 
silenced RWPE-1 cells using RNeasy Mini kit (Qiagen, Hilden, Germany) 
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according to manufacturer’s protocol. RNA was treated with DNaseI to 
remove all traces of genomic DNA. Triplicate RNA samples for each group 
were sent to Origen Labs (Origen Laboratories Pte Ltd, Singapore) for 
hybridization to Affymetrix Human U133 Plus 2.0 Arrays (Affymetrix Inc, 
California, United States of America). Microarray data was analysed using the 
2 softwares: Genespring and Expression Console®. The criteria for 
determining genes that are differentially expressed are of fold change values & 
2 and P-values < 0.05. 
In this process, QC metrics were performed to determine data quality. These 
include checks for 3’ to 5’ ratio of housekeeping genes, presence of spike 
controls, background value, raw Q noise, scaling factor and percent genes 
presence.  
The 3’ to 5’ ratio of housekeeping genes measures the efficiency of the cDNA 
synthesis reaction. Background value is a measure of the signal intensity 
caused by auto fluorescence of the array surface and non-specific target 
binding. The raw Q noise values result from small variations in the digitized 
signal observed by the scanner when it samples the array’s surface. The 
scaling factor then measures the array’s brightness which varies from one to 
the other. Within a single experiment, the scaling factor values should be 
within three-fold of one another. Bacteria spike controls serve as probe sets 
with signal values to highlight any potential problems with the hybridization 
procedure and subsequent washing and staining steps. Lastly, poly A spike 
controls consist of a set of polyadenylated RNA spikes to identify any 
problems with the target preparation.  
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All six samples were reported to pass assay QC check points and were then 
hybridized to Affymetrix Human U133 Plus 2.0 Arrays.  
 
2.1.17    Gene expression data analysis 
Upon receiving the study report from Origen Labs (Origen Laboratories Pte 
Ltd, Singapore), the .CEL files were processed and normalized using 2 
different analysis softwares: Genespring and Expression Console®. 
Expression Console® Software (Expression Console®; 
http://www.affymetrix.com/support/technical/software_downloads.affx) 
application takes probe cell intensity files (*.CEL) and creates probe level 
summarization files (*.CHP) using the selected algorithm workflow. It 
incorporates three algorithms: RMA, PLIER and iterPLIER 
(www.affymetrix.com). Nonetheless, for this project, only the default RMA 
algorithm was employed. 
 
2.1.18    Functional categorization of genes with DAVID 
Differentially expressed genes were functionally categorized using DAVID 
Functional Annotation Tool (DAVID; 
http://david.abcc.ncifcrf.gov/summary.jsp). The tool agglomerates species-
specific gene/protein identifiers from a variety of public genomic resources 
such as NCBI, PIR and Uniprot/SwissProt. Employing an algorithm, DAVID 
groups related genes based on the agreement of sharing similar annotation 
terms by Kappa statistics. Kappa result ranges from 0 to 1. The higher the 
value of Kappa, the stronger is the agreement between two genes. Kappa more 
than 0.7 typically indicates that the agreement between two genes is strong. 
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2.2 Expression analysis of HS3ST3B1 in prostate adenocarcinoma 
tissues using immunohistochemistry 
 
2.2.1    Tissue microarray samples and clinicopathological data 
 
Archived prostate adenocarcinoma tissue specimens were obtained from the 
Department of Pathology, Singapore General Hospital. These samples were 
collected from 394 patients who underwent transurethral resection of the 
prostate from 2000 to 2010. Under supervision, targeted areas of the 
specimens were identified and used for tissue microarray construction, with 
two cores of tissue taken from each formalin-fixed paraffin-embedded sample 
block. In addition, 15 regular sections of low-grade prostate adenocarcinoma 
samples were obtained.  
With the guidance of a pathologist, clinicopathological data were retrieved 
from the database and collected for statistical analysis. These data include the 
following parameters: age, gleason sum, tumour size, stage, unilateral/bilateral 
lobular occurrence as well as absence or presence of HGPIN, extraprostatic 
extension, seminal vesicle involvement, lymphovascular invasion, perineural 
invasion and nodular metastasis. Ethics approval was obtained from the 
Institutional Review Board, Singapore General Hospital. 
 
2.2.2    Tissue microarray construction 
 
Under the supervision of a histotechnologist, the tissue microarrays were 
constructed on the Beecher arrayer with the 2 mm punch. The TMA map was 
designed by the technologist, which serves as a guideline to arrange the 
paraffin blocks to be arrayed (Badve). These blocks were retrieved earlier and 
their corresponding slides were reviewed by the pathologist. 2 tumour areas of 
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interest were marked on each slide by the pathologist. Using a marker pen, 
these corresponding areas were then circled on the paraffin block and the 
samples were arrayed on to a ‘recipient’ blank block (Tan et al., 2005). Each 
patient case has thus 2 tumour areas arrayed for immunohistochemical 
staining.    
 
2.2.3    Immunohistochemical staining 
 
Polyclonal antibody targeting HS3ST3B1 was used as shown in Table 2.6. 
The tissues were firstly deparaffinized and rehydrated. Endogenous peroxidase 
activity was then quenched with 3% aqueous hydrogen peroxide for 30 
minutes and the tissues were washed in Tris-buffered saline (pH 7.6) thrice 
thereafter. The tissue sections were subsequently blocked with horse serum for 
1 hr at room temperature. All sections were then incubated overnight with 
HS3ST3B1 antibody at 40C. After 3 washes, the sections were incubated with 
biotinylated secondary antibody for 1 hr at room temperature. This is followed 
by visualisation of the staining using the avidin-biotin-complex technique 
(ABC kit, Vector Laboratories). The sections were counterstained with 
haematoxylin. 
 
Table 2.6 Optimal conditions used for immunohistochemistry 













1:24 1:99 30 min 
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2.2.4    Immunohistochemical evaluation 
 
The expression of HS3ST3B1 in cancerous cells (both nucleus and cytoplasm) 
and stromal compartment of adenocarcinoma specimens was assessed. The 
percentage of cells and compartment stained was recorded, with intensity of 
staining noted as absent (0), weak (1+), moderate (2+) or strong (3+). For each 
tissue section, a weighted average intensity (WAI) was computed as follows: 
'(intensityx x percentage of cells stained with intensityx) ÷ total percentage of 
cells stained. Immunoreactivity score (IRS) was obtained by multiplying WAI 
with the percentage of cells stained. 2 sections from different cores of the 
same specimen were independently scored; and average values for IRS, WAI 
and percentage of cells stained were calculated. 
 
2.2.5    Statistical analysis 
 
Statistical analysis was performed using SPSS for Macintosh Version 21.0, 
employing the Fisher’s Exact Test to determine correlations between the 
immunohistochemical staining results and clinicopathological parameters. A 




















3.1 Expression and functional analysis of HS3ST3B1 in prostate 
cancer  
3.1.1 Expression of HS3ST3B1 in prostate cell lines and tissues 
 A review of the differentially expressed genes in prostate cell lines 
(RWPE-1, LNCaP and PC-3) and microarray study of prostate 
adenocarcinoma and BPH tissues (Teng, 2010) was performed to assess their 
relative fold changes and directional changes. Differentially expressed genes 
of fold change values greater than 2 and p-value < 0.05 with same directional 
changes between corresponding cell lines and tissues were filtered. Literature 
review was done on these filtered genes to assess their novelty and functions. 
HS3ST3B1 was then selected to be the gene-of-interest in this project. It is 
downregulated in prostate cancer cell lines (LNCaP and PC-3) and 
adenocarcinoma tissues. Quantitative real-time polymerase chain reaction 
(qPCR) was subsequently performed to verify its relative fold changes across 





































Figure 3.1 Expression level of HS3ST3B1 in prostate cancer cell lines (PC-3 
and LNCaP) relative to its normal counterpart RWPE-1. Data shows 
significantly lower expression of HS3ST3B1 in PC-3 and LNCaP as compared 
to RWPE-1. The difference is statistically significant (n=3). ‘**’ represents p 











RWPE-1 vs PC-3        p-value = 0.00308 
 
RWPE-1 vs LNCaP    p-value = 0.000221 
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3.2 Functional analysis of HS3ST3B1 in prostate cancer  
 
3.2.1 HS3ST3B1 is effectively silenced in RWPE-1 
 
 To investigate the functional significance of HS3ST3B1 
downregulation in prostate cancer, HS3ST3B1 was silenced in normal prostate 
epithelial cell line RWPE-1. This was done using double-stranded siRNA 
oligonucleotides from Qiagen (Qiagen, Hilden, Germany) with 
Oligofectamine as the delivery reagent. HS3ST3B1 was effectively silenced as 









Figure 3.2 Silencing efficiencies of HS3ST3B1 in RWPE-1 normal prostate 
epithelial cells. Silencing efficiencies were calculated based on qRT-PCR. 
Non-targeting silenced RWPE-1 (n=3); HS3ST3B1 silenced RWPE-1 (n=3). 





3.2.2 HS3ST3B1 is effectively silenced at the protein level 
To examine the functional significance of HS3ST3B1 downregulation 
in prostate cancer, the gene was silenced in normal prostate epithelial RWPE-
1 cells using Qiagen double-stranded siRNA oligonucleotides. HS3ST3B1 was 
optimally silenced at a greater than 70% silencing efficiency for both siRNA 
sequences (Figure 3.2) and protein levels of HS3ST3B1 were also significantly 
reduced by 50.76% and 37.14% for western blot and immunofluorescence 





















                   Non-targeting siRNA     HS3ST3B1 siRNA  
HS3ST3B1 43 kDa 







Figure 3.3 HS3ST3B1 is effectively silenced and its expression is significantly 
reduced at the protein level. Protein levels of HS3ST3B1 silenced RWPE-1 
were reduced by 50.76% and 37.14% for western blot and 
immunofluorescence assays respectively. Non-targeting silenced RWPE-1 
(n=3); HS3ST3B1 silenced RWPE-1 (n=3). ‘*’ represents p < 0.05 and ‘***’ 
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Figure 3.4 Immunofluorescence staining of HS3ST3B1. HS3ST3B1 is 
expressed in both the nucleus and cytoplasm. HS3ST3B1 silenced RWPE-1 
cells (B) exhibit a lower intensity of staining as compared to its scrambled 















3.2.3 HS3ST3B1 silencing increased RWPE-1 proliferation 
 
 Cell proliferation was performed using CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) (Promega Corporation, Madison, 
Wisconsin, USA). This assay contains a tetrazolium compound, [3-(4,5-
dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] which is bioreduced by NADPH or NADH of 
dehydrogenase enzymes in metabolically active cells into a coloured formazan 
product (Promega, 2012). Measurement of absorbance of the formazan 
product at 490nm (Cory et al., 1991) indicated an increase in cellular 
proliferation by 6.04% (Sequence 1) and 7.18% (Sequence 2) after silencing 
HS3ST3B1 in RWPE-1 cells, 48 hours post-transfection as compared to its 



































Figure 3.5 HS3ST3B1 increased RWPE-1 proliferation. Non-targeting silenced 
RWPE-1 (n=3); HS3ST3B1 silenced RWPE-1 (n=3). ‘*’ represents p < 0.05; 












3.2.4 HS3ST3B1 silencing increased RWPE-1 migration 
 
Acquisition of cancerous phenotypes typically involves an increase in 
the ability of cells to migrate and invade into the extracellular matrix. To 
examine whether the inhibition of HS3ST3B1 in normal prostate epithelial 
cells would result in a progression to malignancy, transwell migration 
chambers were used to test the migratory ability of HS3ST3B1 silenced 
RWPE-1 cells. It was found that migration of RWPE-1 was increased by 
127.79% (Sequence 1) and 133.85% (Sequence 2) after HS3ST3B1 silencing, 






































Figure 3.6 HS3ST3B1 increased RWPE-1 migration. Non-targeting silenced 
RWPE-1 (n=3); HS3ST3B1 silenced RWPE-1 (n=3). ‘**’ represents p < 0.01; 












3.2.5 HS3ST3B1 silencing increased RWPE-1 invasion 
 
The ability of cells to invade into the basement membrane is a 
hallmark of malignancy. Likewise, to examine whether HS3ST3B1 
downregulation in normal prostate epithelial cells would result in a 
progression to malignancy, MatrigelTM invasion chambers were used to test 
the invasive ability of HS3ST3B1 silenced RWPE-1 cells. It was found that 
invasion of RWPE-1 was increased by 253.65% (Sequence 1) and 581.24% 
(Sequence 2) after HS3ST3B1 silencing, at 72 hours post-transfection as 



















































Figure 3.7 HS3ST3B1 increased RWPE-1 invasion. Non-targeting silenced 
RWPE-1 (n=3); HS3ST3B1 silenced RWPE-1 (n=3). ‘**’ represents p < 0.01 












3.2.6 HS3ST3B1 silencing decreased RWPE-1 adhesion to collagen type 
I and fibronectin 
The ability of a cell to adhere to the extracellular matrix can possibly 
affect its migration and invasion into its surrounding tissues. 
Glycosaminoglycan chains have been known to affect cell-ECM and cell-cell 
adhesion. The inhibition of HS3ST3B1 in RWPE-1 cells reduced their ability 
to adhere to collagen type I and fibronectin. A reduction of 24.58% (Sequence 
1) and 24.75% (Sequence 2) was observed for the adhesion assay to collagen. 
In the case of fibronectin, a significant reduction of 16.55% (Sequence 2) was 























     
 
 
     
 
 
Figure 3.8 HS3ST3B1 decreased RWPE-1 adhesion to collagen type I and 
fibronectin. Non-targeting silenced RWPE-1 (n=7); HS3ST3B1 silenced 
RWPE-1 (n=7 or 5). ‘**’ represents p < 0.01 and ‘*’ represents p < 0.05; 













Sequence 1 Sequence 2 
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3.2.7 HS3ST3B1 shRNA work  
 
3.2.7.1 HS3ST3B1 shRNA plasmid amplification and transfection into 
RWPE-1 
To investigate the functional significance of HS3ST3B1 
downregulation in prostate cancer, we attempted to stably silence HS3ST3B1 
in normal prostate epithelial cell line RWPE-1. This was done by amplifying 
and transforming shRNA plasmids from SABiosciences (SABiosciences, 
Qiagen, USA) into competent E.coli cells. The plasmids consisting of a 
negative sequence and four HS3ST3B1 sequences are as listed in Table 2.5. 
These amplified plasmids were then transfected into RWPE-1 cells using 
Lipofectamine 2000 as the delivery reagent. HS3ST3B1 was assayed to be 




Figure 3.9 HS3ST3B1 shRNA plasmid transfection in RWPE-1 normal 
prostate epithelial cells. Numbers represent the number of clones of cells 
(from an original of 24 plated wells per sequence) selected for expansion. 
Only sequences 1 and 2 yielded optimal silencing efficiencies above 70%. 
Silencing efficiencies were calculated based on qRT-PCR. Non-targeting 





3.2.7.2 HS3ST3B1 silencing increased RWPE-1 proliferation and 
adhesion to collagen type I but decreased RWPE-1 migration and 
invasion 
 The single clone from shRNA plasmid sequence 2 had yielded the 
highest silencing efficiency of 90.4% and was further expanded for cellular 
phenotypic assays. It was shown to significantly increase RWPE-1 
proliferation and adhesion to collagen type I, and to decrease RWPE-1 
migration and invasion. (Figure 3.10) Subsequent verification of its silencing 
efficiency however demonstrated a dismal level below 70%. The following 
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Figure 3.10 Effects of HS3ST3B1 silencing on RWPE-1 cellular behaviour. 
[A] and [B] HS3ST3B1 silencing increased RWPE-1 proliferation and 
adhesion to collagen type I. Non-targeting silenced RWPE-1 (n=8); 
HS3ST3B1 silenced RWPE-1 (n=8). [C] and [D] HS3ST3B1 silencing 
impeded RWPE-1 migration and invasion. Non-targeting silenced RWPE-1 
(n=3); HS3ST3B1 silenced RWPE-1 (n=3). ‘***’ represents p < 0.001 and 









3.2.8 HS3ST3B1 may act through OPN3 to exert its tumour suppressive 
effects 
 Microarray study was performed to elucidate the pathway responsible 
for the observed cellular behaviour. Triplicate RNA samples for each group 
were sent to Origen Labs for hybridization to Affymetrix Human U133 Plus 
2.0 Arrays. The quality of RNA samples is good, having OD260/OD280 ratios of 
2.04 to 2.11 with concentrations ranging from 291.99 ng/ul to 454.59 ng/ul 
and RIN values of 9.7 to 9.9. Array QC metrics data were accessed and the 
values obtained fall within the acceptable ranges. The 3’ to 5’ GAPDH ratio in 
this study ranges from 0.38 to 0.42, deemed satisfactory in accordance to the 
ideal ratio of 1 (with an upper limit of approximately 3). The background 
values are consistent, ranging from 37.31 to 41.00, which ensures that accurate 
comparisons can be performed. The raw Q noise values for this project are 
also consistent, ranging from 1.14 to 1.25. In a single experiment, the scaling 
factor values should be within three fold of one another and all values for this 
study fall within the acceptable range. Table 3.1 and Figure 3.11 are adapted 
from the study report obtained from Origen Labs. 
Genespring analysis has yielded a total of 41 differentially expressed 
(fold change value of at least 2 and p-value < 0.05) genes. Using the same 
filtering criteria, Expression Console® analysis on the other hand yielded a 
total of 9 differentially expressed genes. After literature review of all the 
upregulated genes, opsin 3 (OPN3) was selected for downstream silencing. 
The expression level of OPN3 was verified through RT-PCR to be upregulated 
upon HS3ST3B1 knockdown. (Figure 3.13)   
Results 
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Using Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) 2012, the differentially expressed genes were 
functionally annotated and categorised. The tool termed Functional 
Annotation Clustering was employed to group similar annotations together to 
allow a better categorization of the various functions (Dennis et al., 2003). 
DAVID has clustered these genes to partake in the following functions of 






















Table 3.1 Adapted from study report, indicating good quality of RNA samples 
sent for processing. (A) OD260/OD280 ratios, concentrations and RIN values of 









Ther –ve (I) AFG1184-13 2.106 291.99 9.8 
Ther –ve (II) AFG1184-14 2.105 373.05 9.9 
Ther –ve (III) AFG1184-15 2.080 341.31 9.8 
Ther S2 (I) AFG1184-16 2.042 352.05 9.7 
Ther S2 (II)! AFG1184-17 2.097 328.61 9.9 









Raw Q % Present 
Ther –ve (I) 37.31 0.38 1.00 1.14 46.2 
Ther –ve (II) 39.28 0.42 1.00 1.14 44.0 
Ther –ve (III) 40.89 0.41 1.00 1.25 44.7 
Ther S2 (I) 40.25 0.38 1.00 1.21 43.3 
Ther S2 (II)! 41.00 0.42 1.00 1.21 43.8 




































Figure 3.11 Adapted from study report, indicating good quality of RNA 
samples sent for processing. (A) Gel like image from Agilent Bioanalyzer 










Figure 3.12 Heatmap indicating the differentially expressed genes upon the 
downregulation of HS3ST3B1. Genespring analysis has yielded a total of 35 






Table 3.2. Genespring analysis of filtered upregulated genes upon microarray 
study. OPN3 was selected after literature review for downstream silencing. 
                                                          

















Figure 3.13 Expression level of OPN3 in RWPE-1 normal prostate epithelial 
cells. Expression level was calculated based on qRT-PCR, indicating an 
upregulation of OPN3 in HS3ST3B1 silenced RWPE-1 cells. Non-targeting 
silenced RWPE-1 (n=3); HS3ST3B1 silenced RWPE-1 (n=3). ‘**’ represents 










Gene symbol Absolute fold 
change 
p-value 
OPN3 2.1555448 4.63548E-05 
WHSC1 2.0595179 0.00012981842 
FAM35A 2.158153 0.000021711485 
SULT1E1 2.0987227 0.0009455873 
MACC1 2.063609 0.0007786657 
KLRC1/KLRC2 2.379295 0.0003658606 
Results 
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3.3 Functional analysis of OPN3 in prostate cancer  
 
3.3.1 OPN3 is effectively silenced in RWPE-1 
 
To investigate the functional significance of OPN3 upregulation in 
HS3ST3B1 silenced RWPE-1 cells, OPN3 was firstly silenced in RWPE-1. 
Single gene silencing was performed prior to double knockdown of 
HS3ST3B1 and OPN3 to verify any effects due to OPN3 silencing alone. This 
was done using double-stranded siRNA oligonucleotides from Qiagen with 
Oligofectamine as the delivery reagent. OPN3 was effectively silenced at a 
silencing efficiency of 77.1% as compared to the non-targeting scrambled 






Figure 3.14 Silencing efficiency of OPN3 in RWPE-1 normal prostate 
epithelial cells. Silencing efficiency was calculated based on qRT-PCR. Non-
targeting silenced RWPE-1 (n=3); OPN3 silenced RWPE-1 (n=3). ‘**’ 










3.3.2 OPN3 silencing has no effects on RWPE-1 migration and invasion 
 
 In order to verify the biological functions of OPN3 and check if 
silencing OPN3 has any effects on prostate cellular behaviour, phenotypic 
assays were performed after silencing OPN3 in RWPE-1 cells. Both migration 
and invasion assays indicated no significant effects 72 hours post-transfection 









Figure 3.15 OPN3 has no effects on prostate cellular migration and invasion. 
Non-targeting silenced RWPE-1 (n=3); OPN3 silenced RWPE-1 (n=3). 







3.3.3 OPN3 silencing decreased RWPE-1 adhesion to collagen type I and 
fibronectin 
A trend similar to HS3ST3B1 knockdown was observed in the context 
of OPN3 silencing. The inhibition of OPN3 in RWPE-1 cells reduced their 
ability to adhere to collagen type I and fibronectin. A reduction of 15.05% was 
observed for the adhesion assay to collagen. In the case of fibronectin, a 








Figure 3.16 OPN3 decreased RWPE-1 adhesion to collagen type I and 
fibronectin. Non-targeting silenced RWPE-1 (n=7); OPN3 silenced RWPE-1 
(n=7). ‘**’ represents p < 0.01 and ‘*’ represents p < 0.05; Statistical test was 
performed using unpaired T-test. 
Results 
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3.4 Immunohistochemical analysis of HS3ST3B1 in prostate cancer  
 




A total of 394 cases were stained using immunohistochemistry, out of 
which 33 are either dropped during the harsh immunohistochemical process of 
staining or which exhibit absence of adenocarcinoma regions. These samples 
were collected from patients who underwent transurethral resection of the 
prostate from 2000 to 2010. The clinicopathological details of the 361 cases 
used for immunohistochemical analysis are as shown in Table 3.3 below. 
 
Table 3.3. Clinicopathological details of the 361 cases for 
immunohistochemical analysis 
 

























Seminal vesicle involvement 
Positive 
Negative 
















































































3.4.2 Expression of HS3ST3B1 in prostate cancer 
 
 









Figure 3.17 Immunohistochemical staining of HS3ST3B1. There is good 
cytoplasmic (A) and nuclei (B) staining of cells as well as stromal (C) staining 










3.4.3 Associations of HS3ST3B1 immune reactive scores in prostate 
cancer with clinicopathological parameters 
 
Table 3.4. Summary of the distribution of the number of cases scored for 
different arbitrary cut-offs for IRS 
 
Immuno 
Score Component Cut-Offs No. of cases % of cases 
! 35 337 93.4 Epithelial 
Cytoplasm > 35 24 6.6 
! 35 230 63.7 Epithelial 
Nucleus > 35 131 36.3 
! 80 324 89.8 
IRS 
Peritumoural 






























3.4.3.1   Cytoplasm of epithelial cells 
The following table indicates the distribution of the cases and the 
analysed p-values for HS3ST3B1 expression in the epithelial cytoplasm 
component of prostate cancer tissues, for IRS at its cut-off. 
Table 3.5. Histological parameters of prostate cancer correlated with IRS of 
epithelial cytoplasm HS3ST3B1 positive cells. Highlighted box indicative of 
statistically significant result. 
 
Immuno Reactivity Score Parameters  ! 35 > 35 p-value 
(< 7) 84 3 Gleason sum (& 7) 253 21 0.220 
Absence 41 4 HGPIN Presence 248 16 0.509 
Absence 188 15 Extraprostatic 
extension Presence 83 2 0.167 
Absence 265 18 Seminal vesicle 
involvement Presence 10 1 
0.527 
Absence 276 17 Lymphovascular 
invasion Presence 25 3 
0.400 
Absence 140 10 Perineural 
invasion Presence 169 10 0.818 
Absence 216 16 Nodular 
metastasis Presence 55 1 0.210 
Unilateral 13 1 Lobular 
occurrence Bilateral 258 16 0.582 
! 88 333 24 Age > 88 4 0 1.000 
! 96 269 18 Tumour size > 96 8 0 1.000 


















Score Parameters p-value Remarks 
IRS35 Stage 0.027 High IRS – pT2 
 
3.4.3.2   Nucleus of epithelial cells 
The following table indicates the distribution of the cases and the 
analysed p-values for HS3ST3B1 expression in the epithelial nucleus 
component of prostate cancer tissues, for IRS at its cut-off. 
Table 3.7. Histological parameters of prostate cancer correlated with IRS of 
epithelial nucleus HS3ST3B1 positive cells. Highlighted box indicative of 
statistically significant result. 
 
Immuno Reactivity Score Parameters  ! 35 > 35 p-value 
(< 7) 61 26 Gleason sum (& 7) 169 105 0.162 
Absence 25 20 HGPIN Presence 188 76 0.054 
Absence 140 63 Extraprostatic 
extension Presence 71 14 0.013 
Absence 207 76 Seminal vesicle 
involvement Presence 4 7 
0.014 
Absence 201 92 Lymphovascular 
invasion Presence 17 11 
0.402 
Absence 88 62 Perineural 
invasion Presence 129 50 0.014 
Absence 169 63 Nodular 
metastasis Presence 42 14 0.867 
Unilateral 6 8 Lobular 
occurrence Bilateral 205 69 0.014 
! 88 229 128 Age > 88 1 3 0.138 
! 96 206 81 Tumour size > 96 6 2 1.000 










Score Parameters p-value Remarks 
Extraprostatic 
extension 0.013 
High IRS – Absence of 
extraprostatic extension 
Perineural invasion 0.014 High IRS – Absence of perineural invasion 
Lobular occurrence 
(unilateral/bilateral) 0.014 
High IRS – Unilateral 
lobular occurrence 








3.4.3.3   Peritumoural stroma 
The following table indicates the distribution of the cases and the 
analysed p-values for HS3ST3B1 expression in the peritumoural stroma 
component of prostate cancer tissues, for IRS at its cut-off. 
 
Table 3.9. Histological parameters of prostate cancer correlated with IRS of 
HS3ST3B1 positive peritumoural stroma. Highlighted box indicative of 
statistically significant result. 
 
 
Immuno Reactivity Score Parameters  ! 80 > 80 p-value 
(< 7) 79 8 Gleason sum (& 7) 245 29 0.840 
Absence 44 1 HGPIN Presence 234 30 0.062 
Absence 177 26 Extraprostatic 
extension Presence 81 4 0.055 
Absence 252 31 Seminal vesicle 
involvement Presence 11 0 
0.613 
Absence 263 30 Lymphovascular 
invasion Presence 25 3 
1.000 
Absence 134 16 Perineural 
invasion Presence 161 18 0.858 
Absence 207 25 Nodular 
metastasis Presence 51 5 0.811 
Results 
! )%!
Unilateral 13 1 Lobular 
occurrence Bilateral 245 29 1.000 
! 88 320 37 Age > 88 4 0 1.000 
! 96 256 31 Tumour size > 96 8 0 1.000 
pT2 169 26 Stage pT3 84 3 0.010 
 
 




Score Parameters p-value Remarks 




3.4.3.4   HS3ST3B1 expression between pT2 and pT3 stages 
High HS3ST3B1 expression has been demonstrated to correlate with a 
lower pathological pT2 stage in all the 3 compartments of epithelial 
cytoplasm, nucleus and peritumoural stroma. The following figure illustrates 
representative images of the differential HS3ST3B1 staining between the pT2 







Figure 3.18 HS3ST3B1 expression in pT2 and pT3 stages. There is a stronger 
cytoplasmic, nuclei and stromal HS3ST3B1 staining in the pT2 stage (A) as 
compared to the pT3 stage (B). The stronger staining is reflected by a greater 








3.5 Silencing of SULF1 in prostate cancer  
 
3.5.1 Optimisation of SULF1 silencing 
 
To investigate the functional significance of SULF1 downregulation in 
prostate cancer, we attempted to silence SULF1 in normal prostate epithelial 
cell line RWPE-1. This was done using double-stranded siRNA 
oligonucleotides from Ambion (Ambion, Inc / Applied Biosystems) with 
Oligofectamine as the delivery reagent. Despite optimising various 
transfection parameters such as siRNA concentration, cell seeding density and 
using another cell line MKN7 (as SULF1 was effectively silenced in MKN7 
by a fellow postgraduate student), SULF1 was not effectively silenced. The 
highest silencing efficiency obtained was 24.2% for SULF1 siRNA sequence 
2, with an optimal negative control silencing of 95.8% obtained. 




























4.1 HS3ST3B1 is a tumour suppressor in prostate cancer  
 Heparan sulphate is a highly sulphated polysaccharide that is 
biosynthesized in the Golgi apparatus and can be found attached to 
proteoglycans on the surface of mammalian cells as well as in the extracellular 
matrix. HS proteoglycans such as the syndecans and glypicans are cell surface 
bound whereas perlecan, agrin and collagen XVIII are secreted ECM 
proteoglycans found in the basement membrane (Bishop et al., 2007; Grobe et 
al., 2002). Signaling molecules such as the growth factors, chemokines and 
cytokines bind to HS present on these proteoglycans which then act as co-
receptors. Heparan sulphate, through its interactions with these signaling 
molecules, has thus been able to play important roles in suppressing cancer 
progression, viral infections, blood coagulation, embryonic development and 
wound healing (Alexander et al., 2000; Bernfield et al., 1999; Liu and Thorp, 
2002; Xu et al., 2005). Sulphation of the polysaccharide occurs in the form of 
3-O-sulphation and 6-O-sulphation of glucosamine residues, as well as 2-O-
sulphation of glucuronic or iduronic residues. The enzymes that carry out 
these sulphation modifications are the 3-O-, 6-O- and 2-O-sulphotransferases 
respectively (Esko and Selleck, 2002). 
Heparan sulphate (glucosamine) 3-O-sulphotransferase 3B1 
(HS3ST3B1) transfers sulphate from PAPS (adenosine 3)-phosphate 5)-
phosphosulphate) to the 3-OH position of glucosamine residue to form 3-O-
sulphated HS. Seven different isoforms of 3-O-sulphotransferases have been 
identified. They are the HS3ST1, -2, -3A1, -3B1, -4, -5 and -6. Particularly, 
Discussion 
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HS3ST3B1 and HS3ST3A1 sulphate identical disaccharides and have highly 
identical amino acid sequences in their sulphotransferase domains (Liu et al., 
1999; Xu et al., 2005). Furthermore, it has been shown that these isoforms 
exhibit tissue-specific expression. Hence, each isoform is capable of 
generating tissue-specific heparan sulphate which possesses unique biological 
functions. For instance, 3-O-sulphated HS has been demonstrated to serve as 
an entry receptor for herpes simplex virus type 1 (HSV-1) (Shukla et al., 1999; 
Tiwari et al., 2004).  
In my study, the expression level of HS3ST3B1 was first quantitated in 
prostate cell lines (LNCaP, PC-3 and RWPE-1). HS3ST3B1 was found to be 
downregulated by 9 fold in PC-3 and 122 fold in LNCaP. Since both prostate 
cancer cell lines (LNCaP and PC-3) exhibited a significantly decreased 
HS3ST3B1 expression level relative to normal prostate epithelial cell line 
RWPE-1, we hypothesize the potential tumour suppressor role of HS3ST3B1.  
Upon optimal silencing of HS3ST3B1 in RWPE-1 cells, cellular 
phenotypic assays were performed to investigate the effects of downregulating 
HS3ST3B1. We observed that HS3ST3B1 silenced cells demonstrated a 
significant increase in cellular migration, invasion and proliferation, coupled 
with a decrease in cellular adhesion. These results thus support the 
hypothesized tumour suppressor role of HS3ST3B1. 
Hanahan and Weinberg have proposed 6 hallmarks of cancer to entail 
features of cancer cells in sustaining proliferative signaling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis and resisting cell death (Hanahan and 
Weinberg, 2011). Functional analysis of HS3ST3B1 indicates that its 
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downregulation results in the acquisition of cancerous phenotypes – an 
increase in cell motility, invasiveness and growth as well as a reduction in 
cell-cell adhesion. Notably, the observation of a reduced adhesion to 
fibronectin corresponds to literature review of fibronectin containing domains 
that bind to heparan sulphate chains to induce focal adhesion (Bishop et al., 
2007). A reduction in cell-substratum adhesion may hence facilitate cell 
motility and metastasis – the transit and escape of cancer cells to distant 
tissues (Hanahan and Weinberg, 2011). Western blot and immunofluorescence 
assays have demonstrated an effective silencing of HS3ST3B1 at the protein 
level.  
Little information has been known on the functions of 3-O-
sulphotransferases in cancer. Of particular note is this paper which has 
proposed the role of HS3ST3B1 as a novel epithelial-mesenchymal transition 
inducer in pancreatic cancer. Song et al. has demonstrated that an 
overexpression of HS3ST3B1 in pancreatic cancer cells promotes EMT. EMT 
characterizes a loss of cell-cell junctions and adhesion in epithelial cells and 
cytoskeletal rearrangement to confer a switch to a mesenchymal phenotype 
(Thiery and Sleeman, 2006). Furthermore, in vivo studies revealed that 
HS3ST3B1 facilitates angiogenesis. Intriguingly, this study also mentioned 
that the treatment with a histone deacetylase inhibitor, trichostatin-A, in 
pancreatic cancer cells stimulated the expression of HS3ST3B1 (Song et al., 
2011). This leads us to the question of which event causes the other. Due to 
the complexity of the process of EMT that can potentially involve many 
players, it is possible that epigenetic events cause a dysregulation of critical 
heparan sulphate modulators to result in EMT. Epigenetic changes may also 
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work synergistically with HS3ST3B1 to cause EMT. Hence, to comprehend 
the sequential order of these players, the roles of HS3ST3B1 have to be further 
elucidated.  
In addition to downregulating HS3ST3B1 via the siRNA mechanism, 
studies have proposed the use of short hairpin RNA-expressing bacteria to 
elicit RNA interference. Xiang et al. have engineered Escherichia coli 
encoding shRNA against catenin ß-1 (CTNNB1) to induce gene silencing in 
human colon cancer xenografts in vivo (Xiang et al., 2006). This successful 
attempt depicts an alternative RNA interference mechanism that offers a 
feasible in vivo approach useful in advancing the clinical applications of gene 
silencing. 
 The short interfering siRNA approach would still require much 
modifications to attain optimal gene silencing for systemic applications 
(Soutschek et al., 2004). Additionally, non-synthetic siRNA approaches which 
use viral vectors can pose potential safety concerns. In contrast, non-
pathogenic bacteria such as E.coli are far less hazardous and do not require 
target cell receptors for gene silencing (Xiang et al., 2006). For instance, 
intravenous treatment using attenuated Salmonella typhimurium has been 
administered in a Phase I study to melanoma patients (Toso et al., 2002). 
 Furthermore, as the engineered bacteria release the shRNA inside 
target cells, this approach holds the advantage of mitigating Toll-like receptor-
mediated immunostimulatory effect of siRNA (Hornung et al., 2005). The 
shRNA constructs can also be stored, reproduced and amplified.  
 In view of the various advantages of shRNA mechanism, HS3ST3B1 
gene silencing was attempted using this approach. Plasmid amplification was 
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first carried out using E.coli and the shRNA plasmids were subsequently 
extracted. An initial silencing efficiency of 90.4% was obtained with shRNA 
plasmid sequence 2. It was shown to significantly increase RWPE-1 
proliferation and adhesion to collagen type I, and to decrease RWPE-1 
migration and invasion. Upon further validation nonetheless, silencing 
efficiency dropped to a dismal 18%. Subsequently, limiting dilution of stably 
transfected cells as well as siRNA silencing mechanism were performed as 
means of verification. Due to tremendous cell death and slow rate of cell 
growth, the former method of verification was aborted. 
The drastic drop in silencing efficiency can be attributed to the 
derivation of daughter clones from more than one mother cell. In the above 
context, 2 or more clones when mixed together could have resulted in the 
optimal silencing efficiency to be compromised. Prolonged passaging of 
transfected cells might also have caused cells from the ‘bad clone’ (cells of 
undesirable silencing efficiency) to populate at a rate that overwhelms cells 
from the ‘good clone’ (cells of optimal silencing efficiency). 
We understand that the siRNA-triggered gene silencing can be 
achieved by 2 methods: 1) entry of viral or plasmid-based vectors into the 
nucleus for transcription into short hairpin RNAs which would be transported 
to the cytoplasm for cleavage into siRNAs by Dicer (Lares et al., 2010) and 2) 
introduction of synthetic siRNA into the cytoplasm for direct processing by 
RNA-induced silencing complex (RISC) (Jackson and Linsley, 2010). 
Despite the aforementioned various advantages of the shRNA system, 
its main challenge lies in its delivery. The common approach of viral vectors 
poses side effects such as immunotoxicity and mutagenesis (Guo et al., 2010). 
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On the contrary, synthetic siRNAs under repeat administration has been 
reported to achieve long-term silencing. Clinical trials are also currently in 
place for synthetic siRNA-based cancer therapy (Guo et al., 2011; John et al., 
2007). Viewing from this context, the critical focus of this study is to then 
achieve HS3ST3B1 gene silencing via the latter direct approach and study the 
effects of HS3ST3B1 downregulation thereafter.  
Microarray analysis of HS3ST3B1 silenced cells indicates potential 
genes probably acting downstream of HS3ST3B1, of which may also be 
independently responsible for the acquisition of cancerous phenotypes. 
Genespring and Expression Console® analyses indicate an overlapping of 4 
differentially expressed genes; FAM35A, OPN3, SULT1E1 and WHSC1, 
which are upregulated upon HS3ST3B1 silencing. Taking into account all the 
upregulated genes, 2 of them (WHSC1 and MACC1) are of noteworthy 
mention. 
 
Figure 4.1 Microarray analysis of HS3ST3B1 silencing in RWPE-1 cells. 
Genespring and Expression Console® analyses have yielded a total of 41 and 
9 differentially expressed genes respectively, with an overlapping of 4 genes, 
which are all upregulated. 
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Downregulating HS3ST3B1 in RWPE-1 cells has resulted in increased 
cellular migration, invasion and proliferation, coupled with decreased cellular 
adhesion. Studies have shown that an inhibition of Wolf-Hirschhorn syndrome 
candidate 1 (WHSC1) expression suppresses growth and alters the adhesion 
properties of multiple myeloma cells. WHSC1 is also implicated in the p53 
and integrin signaling pathways (Martinez-Garcia et al., 2011). Additionally, 
high WHSC1 expression is found in small cell lung, skin, bladder and 
gastrointestinal carcinomas. Particularly in bladder cancer, WHSC1 expression 
was found to correlate with tumour aggressiveness (Hudlebusch et al., 2011).  
In the context of Metastasis-associated in colon cancer 1 (MACC1), its 
overexpression was detected in ovarian cancer tissues. Its downregulation was 
found to result in an inhibition of cellular proliferation, migration and 
invasion. Zhang et al. also found that the effects of MACC1 may act via the 
HGF/Met and MEK/ERK pathways (Zhang et al., 2011). In another study, 
Stein et al. observed that MACC1 promotes proliferation and invasion of colon 
cancer cells and tumour growth and metastasis in complementary in vivo 
studies (Stein et al., 2009).  
The above studies suggest that WHSC1 and MACC1 may serve as 
positive regulators of tumour progression, to result in the acquisition of 
cancerous phenotypes observed upon HS3ST3B1 knockdown. These two 
genes however, were not chosen for silencing experiments in RWPE-1 due to 
their low expression levels in these normal prostate epithelial cells. 
Nonetheless, we cannot disregard the important functions that WHSC1 and 
MACC1 may play in the context of a tumour environment. This warrants 
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further investigation in prostate cancer cell lines, which is currently beyond 
the scope of this study. 
Notably, OPN3 is upregulated by approximately 2.2 folds upon the 
downregulation of HS3ST3B1. Recent studies have illustrated the potential 
functions of OPN3 in the pathophysiologies of cancers and asthma. Genome-
wide association study reveals a possible association of OPN3 with single 
nucleotide polymorphisms that may correlate to the overall survival of small 
cell lung cancer patients (Niu et al., 2012). OPN3 may regulate the apoptotic 
pathway to work against 5-fluorouracil chemoresistance and sensitize the 
hepatocellular carcinoma cells (Jiao et al., 2012). Studies have also shown its 
involvement in the pathogenesis of asthma by possibly modulating T-cell 
responses (Agrawal and Shao, 2010; White et al., 2008). There is however, no 
known function of OPN3 in prostate physiology. Due to its favourable basal 
expression in RWPE-1, we decided to firstly silence this gene in RWPE-1 to 
explore its functions in normal prostate physiology. 
It was found that OPN3 silencing had no effects on RWPE-1 
proliferation, migration and invasion but that it decreased RWPE-1 adhesion 
to collagen type I and fibronectin. These results are interesting and to further 
explore if OPN3 acts downstream of HS3ST3B1, we need to perform silencing 
of both HS3ST3B1 and OPN3 in RWPE-1 cells. As RWPE-1 is a normal 
prostate epithelial cell line, it is not surprising that silencing OPN3 had no 
effects on its migration and invasion. If OPN3 acts downstream of HS3ST3B1, 
we may then be able to observe a reduction in the migrative and invasive 
abilities of HS3ST3B1-silenced RWPE-1 cells. Given that OPN3 does not 
affect normal prostate physiology, we may conclude that it is not significant in 
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altering the state of prostate cellular physiology and that any effects observed 
upon double silencing of HS3ST3B1 and OPN3 can be attributed to the 
principal tumour suppressive role of HS3ST3B1.  
Nonetheless, due to time constraints, double silencing of HS3ST3B1 
and OPN3 is proposed as a potential future work. 
 
4.2 HS3ST3B1 as a potential prostate cancer biomarker  
 
 The pathologist is more often than not, required to assess a tumour’s 
aggressiveness aside from primarily diagnosing the presence of carcinoma. 
Despite Gleason score being accepted as a clinically significant parameter, 
there is always a need to understand the potential usefulness and efficacy of 
other prognostic parameters to better predict prostate cancer’s progression.  
 In this study, in vitro results have postulated the potential tumour 
suppressor role of HS3ST3B1. We are next interested to ascertain if 
HS3ST3B1 can correlate with any prognostic clinicopathological parameters 
and if so, to assess its potential as a prostate cancer biomarker. 
 A total of 394 cases were collected to stain for the expression level of 
HS3ST3B1 in the epithelial cytoplasm and nucleus as well as the peritumoural 
stroma compartments of the tissue sections. Only the adenocarcinoma regions 
were scored and analysed for statistical significance. There are 33 cases which 
are either dropped during the harsh immunohistochemical process of staining 
or exhibit absence of adenocarcinoma regions. The latter happened due to 
technical difficulties in the selection of adenocarcinoma regions and 
subsequent punching of tissue cores. 
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 We observed that the HS3ST3B1 immunoscores for all 3 
compartments (epithelial cytoplasm, epithelial nucleus and peritumoural 
stroma) correlate with clinicopathological parameters such as pathological 
staging, lobular occurrence (unilateral/bilateral), extraprostatic extension and 
perineural invasion. A higher expression level of HS3ST3B1 corresponding to 
higher immunoscores of IRS, WAI and TPS seems to indicate a better 
prognosis for prostate cancer. 
 Concurrently, the epithelial nucleus demonstrates a statistical 
significance for both parameters of extraprostatic extension and perineural 
invasion. Literature review has likewise reflected the potential association of 
perineural invasion with extraprostatic extension, as extraprostatic invasion 
occurs through the neurovascular bundles in 85% of the cases studied (Villers 
et al., 1989). Perineural invasion has also been associated with a higher risk of 
lymph node metastasis (Stone et al., 1998).  
 HGPIN has been defined as the abnormal proliferative change in 
prostatic ducts and acini to exhibit a nuclear morphological pattern similar to 
that of prostate adenocarcinoma. It is also a precursor lesion for prostate 
cancer with a malignant potential not necessarily restricted to the site of 
HGPIN focus (Girasole et al., 2006). This parameter is likely to be associated 
(p = 0.054) with the epithelial nuclear expression of HS3ST3B1. A greater 
HS3ST3B1 expression has yielded an absence of HGPIN. This potentially 
correlates to a lower risk of HGPIN and hence reduces the likelihood of 
prostate adenocarcinoma. 
 The development of an accurate pathological staging system is 
essential for determining the prognosis of prostate cancer. The definition of a 
Discussion 
! *(!
prostate T2 disease is that of palpable organ-confined tumour. This is further 
subdivided into three categories of T2a (unilateral tumour involving half of a 
lobe or less), T2b (unilateral tumour involving more than half a lobe) and T2c 
(bilateral tumour) (van Oort et al., 2008). This subclassification has remained 
controversial, with studies proposing the unlikelihood of a large tumour 
involving more than half a lobe without extending into the other lobe 
(Eichelberger and Cheng, 2004; Quintal et al., 2006). In this study, a simple 
comparison between pT2 and pT3 stages was employed and it was found that 
a higher HS3ST3B1 expression level corresponds to a prostate-confined 
tumour in all three compartments of epithelial cytoplasm, nucleus and 
peritumoural stroma, indicating a better prognosis. 
 Amongst the 3 compartments scored, HS3ST3B1 staining in the 
epithelial nucleus exhibits the most number of significant correlations with the 
clinicopathological parameters. This is not surprising as heparan sulphate is 
biosynthesized in the Golgi apparatus which is located near the nucleus. It has 
also been suggested that heparan sulphate can localize to the nucleus (Bishop 
et al., 2007). As HS3ST3B1 is a biosynthetic enzyme of heparan sulphate, the 
extent and degree of its expression may be the most prominent in the nucleus. 
Additionally, high IRS, WAI and TPS of HS3ST3B1 staining in the epithelial 
nucleus likely correspond (p-values are close to statistical significance) to a 
lower risk of HGPIN – also defined as nuclear atypia. The definition of 
HGPIN in itself suggests the role of the epithelial nucleus. The nucleus 
compartment of high HS3ST3B1 expression level correlates with a lower risk 
of extraprostatic extension and perineural invasion as well as cancer involving 
a single lobe and lower pT2 stage. This implies the association of a better 
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prognosis with high HS3ST3B1 expression level, supporting the in vitro 
results of HS3ST3B1 as a potential tumour suppressor. 
 Intriguingly, the clinicopathological parameters of seminal vesicle 
involvement (SVI) and Gleason code are inconsistent with the aforementioned 
correlations. SVI has been generally regarded as a parameter of poor prostate 
cancer prognosis. Despite this, Potter et al. have reviewed that divergent 
pathologic definitions of SVI likely contribute to the disparate reported 
prostate cancer recurrence rates (Potter et al., 2000). 
 In this study, cases are merely differentiated into absence or presence 
of SVI. There is no detailed pathological examination of the three different 
patterns of SVI. In a study of the prognostic significance of SVI by Ohori et 
al., they have mentioned the three types of SVI involvement (Ohori et al., 
1993). Type I involvement entails a metastatic spread along the ejaculatory 
ducts whereas type II consists of an extraprostatic spread through the capsule. 
Type III, which is the rarest, is characterized by the finding of isolated 
deposits of cancer in the seminal vesicles without a primary cancer in the 
prostate. Ohori et al. concluded that depending on the specific mechanism of 
involvement and pathologic features of the primary tumour, the prognostic 
significance of SVI may not be evenly ominous/unpleasant.  
 Gleason coding in this study has a cut-off at 7 to stratify the patients 
into two groups. Those with a Gleason sum of & 7 have a worse prognosis. 
This Gleason coding is relevant to the literature which usually has a cut-off at 
7 (Algaba et al., 2005). Out of the 3 immunoscores (IRS, WAI and TPS) 
analysed for the 3 compartments of epithelial cytoplasm, nucleus and 
peritumoural stroma, the TPS of the epithelial nucleus and WAI of the 
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peritumoural stroma demonstrated a trend of higher HS3ST3B1 expression 
level correlating to Gleason sum & 7, implying a worse prognosis (only data 
for IRS is presented in the Results section). No statistical significance was 
observed for the other immunoscores, despite various other significant 
correlations of greater HS3ST3B1 expression to a better prognosis (absence of 
extraprostatic extension and perineural invasion etc). This may indicate that 
Gleason sum should be viewed as an independent parameter and that there are 
no associations with other prognostic clinicopathological parameters in this 
study.  
 The above inconsistencies may also be attributed to the heterogeneous 
nature of prostate cancer. The inherent heterogeneous mixture of cell 
populations with different genetic makeup within the tissues means the 
difficulty therein of an absolute extrapolation to prostate cell lines which 
represent a homogenous cell population originating from the epithelial cells.   
Albeit some disparities of the results, this study has indicated that 
HS3ST3B1 may play a potential role in mitigating prostate cancer 
progression, by being correlated to a reduced risk of extraprostatic extension 
and perineural invasion as well as cancer involving a single lobe and lower 
pT2 stage. Due to the heterogeneity of the disease, HS3ST3B1 may halt the 
process of progression to malignancy, disrupt the progression of localized 
prostate cancer to its metastatic state or decelerate metastatic prostate cancer 
from becoming life-threatening. Much has to be further researched upon to 
clearly define the roles of HS3ST3B1. This immunohistochemical study has 
nonetheless emphasized the important functions of HS3ST3B1 in prostate 
physiology and yielded interesting results worthy of further investigation.   
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Chapter 5  
 
Conclusions and Future Work 
 
5.1 Delineating the functional significance of HS3ST3B1 in prostate 
cancer  
 In the context of gene-targeted therapy, the identification of molecular 
targets remains a paramount challenge. Due to the heterogeneous nature of 
prostate cancer manifestations ranging from an asymptomatic to the severe 
life-threatening form, novel therapeutic targets would provide alternatives to 
the conventional treatment regimens and aid in the management of the disease. 
 Expression screens of the differentially expressed genes in prostate 
cancer cell lines and adenocarcinoma tissues as compared to their normal 
counterparts were previously conducted (Teng, 2010). HS3ST3B1 was chosen 
to be the gene of interest in this study due to its downregulation in both 
prostate cancer cell lines and adenocarcinoma tissues. The hypothesis of 
HS3ST3B1 as a tumour suppressor is made.  
 Heparan sulphate sulphotransferase enzyme, HS3ST3B1, was silenced 
in normal prostate epithelial RWPE-1 cells. HS3ST3B1-silenced RWPE-1 
cells demonstrated an increased cellular migration, invasion and proliferation, 
coupled with a decreased cellular adhesion. We can conclude that 
downregulating HS3ST3B1 has resulted in the acquisition of cancer 
phenotypes, hence affirming the tumour suppressor role of HS3ST3B1.   
 Microarray analysis was performed on HS3ST3B1-silenced RWPE-1 
cells and revealed potential downstream genes, particularly OPN3. OPN3 was 
then silenced in RWPE-1 cells to investigate its functions in prostate 
physiology.  
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 These results have highlighted HS3ST3B1 as a tumour suppressor gene 
and a potential therapeutic target. Future work, however, can be done to 
investigate if HS3ST3B1 directs OPN3 to elicit the tumour suppressive effects. 
Double silencing of HS3ST3B1 and OPN3 in RWPE-1 cells can be performed 
with subsequent cellular phenotypic assays to give us a better understanding of 
the mechanism of HS3ST3B1 as a tumour suppressor gene. Since HS3ST3B1 
transfers sulphate from PAPS to the 3-OH position of glucosamine residue to 
form 3-O-sulphated HS, we can explore the functions of heparan sulphate 
glycosaminoglycan chains in prostate cancer. This can be done by using 
heparitinase enzymes to degrade the glycosaminoglycan chains and observing 
the effects thereafter.  
 
5.2 Examining HS3ST3B1 as a potential biomarker in prostate cancer  
 
 Established clinicopathological parameters serve as excellent 
prognostic biomarkers. Nonetheless, the prognostic and treatment challenges 
of prostate cancer have always been present due to its diverse manifestations 
and limitations of the parameters. The identification of useful biomarkers in 
clinical outcome may facilitate the stratification of patients into the 
appropriate treatment regimens and better manage prostate cancer. 
 Association studies of HS3ST3B1 with various clinicopathological 
parameters were conducted. It was found that high HS3ST3B1 expression in 
cancer cells and in peritumoural stroma correlates with a reduced risk of 
extraprostatic extension and perineural invasion as well as cancer involving a 
single lobe and lower pT2 stage. This trend is optimistic of a better prognosis 
and further affirms HS3ST3B1 as an anti-tumour protein. 
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 Albeit the aforementioned promising results, findings were not 
consistent throughout the study. High HS3ST3B1 expression in cancer cells 
and in peritumoural stroma correlates with a greater risk of SVI and Gleason 
sum & 7, which promulgates a worse prognosis.  
 This study has unraveled interesting findings of HS3ST3B1. Though it 
may not be a key predictive biomarker, we should not disregard its importance 
in the physiology of prostate cancer. In order to better determine the principal 
role of HS3ST3B1, long term follow up data such as PSA recurrence rates and 
survival are crucial. Future work can include the acquisition and analysis of 
such data with the expression of HS3ST3B1. 
 In view of the inconsistencies with the in vitro results, overexpression 
studies of HS3ST3B1 can be performed in prostate cancer cell lines to 
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